ºÝºÝߣshows by User: scinticasam / http://www.slideshare.net/images/logo.gif ºÝºÝߣshows by User: scinticasam / Fri, 13 Jun 2025 18:05:48 GMT ºÝºÝߣShare feed for ºÝºÝߣshows by User: scinticasam iNSiGHT DEXA ----- Live Lab Demonstration /slideshow/insight-dexa-live-lab-demonstration/280523305 insightdxa-livedemo-06122025-250613180548-ea506677
In this webinar, we showcased just how fast and easy it is to use the iNSiGHT DEXA imaging system for preclinical body composition and bone mineral density analysis. This quick yet powerful demonstration highlighted the system’s exceptional speed, minimal animal handling requirements, and intuitive workflow—helping researchers reduce time under anesthesia and accelerate their research timelines. During the live session, attendees were guided through a rapid, real-time demonstration of the iNSiGHT DEXA imaging system. The presentation revealed how simple it is to go from scan to data, with key features including: A full-body scan and data generation completed in under 30 seconds, significantly minimizing animal time under anesthesia; A user-friendly software and imaging workflow enabling seamless setup, acquisition, and automatic analysis; Time-saving batch processing tools that streamline routine imaging for greater efficiency. Participants learned: How quickly and easily body composition and bone density data can be acquired using the iNSiGHT DEXA system; How the simplified workflow supports both novice and experienced users in high-throughput environments; Answers to common questions during the interactive Q&A segment. Whether new to DXA or looking to optimize imaging process, this webinar demonstrated how the iNSiGHT DEXA empowers researchers to scan smarter, not longer.]]>
In this webinar, we showcased just how fast and easy it is to use the iNSiGHT DEXA imaging system for preclinical body composition and bone mineral density analysis. This quick yet powerful demonstration highlighted the system’s exceptional speed, minimal animal handling requirements, and intuitive workflow—helping researchers reduce time under anesthesia and accelerate their research timelines. During the live session, attendees were guided through a rapid, real-time demonstration of the iNSiGHT DEXA imaging system. The presentation revealed how simple it is to go from scan to data, with key features including: A full-body scan and data generation completed in under 30 seconds, significantly minimizing animal time under anesthesia; A user-friendly software and imaging workflow enabling seamless setup, acquisition, and automatic analysis; Time-saving batch processing tools that streamline routine imaging for greater efficiency. Participants learned: How quickly and easily body composition and bone density data can be acquired using the iNSiGHT DEXA system; How the simplified workflow supports both novice and experienced users in high-throughput environments; Answers to common questions during the interactive Q&A segment. Whether new to DXA or looking to optimize imaging process, this webinar demonstrated how the iNSiGHT DEXA empowers researchers to scan smarter, not longer.]]> Fri, 13 Jun 2025 18:05:48 GMT /slideshow/insight-dexa-live-lab-demonstration/280523305 scinticasam@slideshare.net(scinticasam) iNSiGHT DEXA ----- Live Lab Demonstration scinticasam In this webinar, we showcased just how fast and easy it is to use the iNSiGHT DEXA imaging system for preclinical body composition and bone mineral density analysis. This quick yet powerful demonstration highlighted the system’s exceptional speed, minimal animal handling requirements, and intuitive workflow—helping researchers reduce time under anesthesia and accelerate their research timelines. During the live session, attendees were guided through a rapid, real-time demonstration of the iNSiGHT DEXA imaging system. The presentation revealed how simple it is to go from scan to data, with key features including: A full-body scan and data generation completed in under 30 seconds, significantly minimizing animal time under anesthesia; A user-friendly software and imaging workflow enabling seamless setup, acquisition, and automatic analysis; Time-saving batch processing tools that streamline routine imaging for greater efficiency. Participants learned: How quickly and easily body composition and bone density data can be acquired using the iNSiGHT DEXA system; How the simplified workflow supports both novice and experienced users in high-throughput environments; Answers to common questions during the interactive Q&A segment. Whether new to DXA or looking to optimize imaging process, this webinar demonstrated how the iNSiGHT DEXA empowers researchers to scan smarter, not longer. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/insightdxa-livedemo-06122025-250613180548-ea506677-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> In this webinar, we showcased just how fast and easy it is to use the iNSiGHT DEXA imaging system for preclinical body composition and bone mineral density analysis. This quick yet powerful demonstration highlighted the system’s exceptional speed, minimal animal handling requirements, and intuitive workflow—helping researchers reduce time under anesthesia and accelerate their research timelines. During the live session, attendees were guided through a rapid, real-time demonstration of the iNSiGHT DEXA imaging system. The presentation revealed how simple it is to go from scan to data, with key features including: A full-body scan and data generation completed in under 30 seconds, significantly minimizing animal time under anesthesia; A user-friendly software and imaging workflow enabling seamless setup, acquisition, and automatic analysis; Time-saving batch processing tools that streamline routine imaging for greater efficiency. Participants learned: How quickly and easily body composition and bone density data can be acquired using the iNSiGHT DEXA system; How the simplified workflow supports both novice and experienced users in high-throughput environments; Answers to common questions during the interactive Q&amp;A segment. Whether new to DXA or looking to optimize imaging process, this webinar demonstrated how the iNSiGHT DEXA empowers researchers to scan smarter, not longer.
iNSiGHT DEXA ----- Live Lab Demonstration from Scintica Instrumentation
]]> 6 0 https://cdn.slidesharecdn.com/ss_thumbnails/insightdxa-livedemo-06122025-250613180548-ea506677-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 An Efficient and Reliable Method to Determine SpO2 in Rodents.pdf /slideshow/an-efficient-and-reliable-method-to-determine-spo2-in-rodents-pdf/279882978 slides-anefficientandreliablemethodtodeterminespo2inrodents-250529190059-482650b8
Accurate, non-invasive physiological monitoring is key to reproducible pre-clinical research studies. While the Rodent Surgical Monitor (RSM+) system has helped many researchers monitor the standard vital signs ECG, respiration, and core temperature in their experimental animals, oxygen saturation – a critical clinical parameter – has often been overlooked or under utilized. Now, a newly launched platform changes that. Featuring patent-pending ECG electrodes with integrated pulse oximetry sensors on the platform with redesigned electronics for cleaner, more reliable data, this next-generation system sets a new standard for precision monitoring during procedures. Clinically, oxygen saturation or SpO2 measurements are made routinely because it directly reflects upon how effectively oxygen is being transported via the blood from the lungs to the entire body. It is a key indicator of respiratory and cardiovascular function used to monitor patients while under anesthesia, confirm and assess respiratory or cardiac conditions, etc. Accurate oxygen saturation monitoring can help prevent organ damage, improve patient outcomes, and support timely clinical interventions. Even though used extensively clinically, oxygen saturation has not been routinely measured in preclinical studies. However, with changing perceptions to increase monitoring and reproducibility of studies, researchers have started to opt for this measurement. The Indus Instruments RSM+ system has a commercially available external thigh clip sensor for SpO2 measurement. However, clip SpO2 sensors depend on proper placement at the desired physical location on the animal (thigh, paw, tail, etc.), proper orientation to minimize respiration artifact, and the need to shave hair at the site of measurement are some of the key requirements. To mitigate and/or minimize these issues, Indus Instruments now offers a newly launched platform (RSMoX) that offers pulse oximetry sensors integrated into ECG electrodes that will detect oxygen saturation in the paw in either mice or rats, greatly reducing placement time and improving the reliability and reproducibility of SpO2 measurements. Oxygen saturation measurements were obtained from the paw with RSMoX system were compared to and validated with the commercially available, Indus external thigh clip sensor and StarrLife (Mouse Ox) thigh clip sensor at baseline (normoxia) and during hypoxia induced using nitrogen gas. The results demonstrated no significant differences between the measurements of the ECG electrode paw sensor versus the clip sensors. The following presentation showcases/illustrates the results of this study as well as demonstrating other features/capabilities of the RSMoX system. Learning Objectives: Understand the importance of comprehensive, non-invasive physiological monitoring – including oxygen saturation – for reproducible animal research outcomes. Learn about the new features of the redesigned Rodent Surgical Monitoring Platform]]>
Accurate, non-invasive physiological monitoring is key to reproducible pre-clinical research studies. While the Rodent Surgical Monitor (RSM+) system has helped many researchers monitor the standard vital signs ECG, respiration, and core temperature in their experimental animals, oxygen saturation – a critical clinical parameter – has often been overlooked or under utilized. Now, a newly launched platform changes that. Featuring patent-pending ECG electrodes with integrated pulse oximetry sensors on the platform with redesigned electronics for cleaner, more reliable data, this next-generation system sets a new standard for precision monitoring during procedures. Clinically, oxygen saturation or SpO2 measurements are made routinely because it directly reflects upon how effectively oxygen is being transported via the blood from the lungs to the entire body. It is a key indicator of respiratory and cardiovascular function used to monitor patients while under anesthesia, confirm and assess respiratory or cardiac conditions, etc. Accurate oxygen saturation monitoring can help prevent organ damage, improve patient outcomes, and support timely clinical interventions. Even though used extensively clinically, oxygen saturation has not been routinely measured in preclinical studies. However, with changing perceptions to increase monitoring and reproducibility of studies, researchers have started to opt for this measurement. The Indus Instruments RSM+ system has a commercially available external thigh clip sensor for SpO2 measurement. However, clip SpO2 sensors depend on proper placement at the desired physical location on the animal (thigh, paw, tail, etc.), proper orientation to minimize respiration artifact, and the need to shave hair at the site of measurement are some of the key requirements. To mitigate and/or minimize these issues, Indus Instruments now offers a newly launched platform (RSMoX) that offers pulse oximetry sensors integrated into ECG electrodes that will detect oxygen saturation in the paw in either mice or rats, greatly reducing placement time and improving the reliability and reproducibility of SpO2 measurements. Oxygen saturation measurements were obtained from the paw with RSMoX system were compared to and validated with the commercially available, Indus external thigh clip sensor and StarrLife (Mouse Ox) thigh clip sensor at baseline (normoxia) and during hypoxia induced using nitrogen gas. The results demonstrated no significant differences between the measurements of the ECG electrode paw sensor versus the clip sensors. The following presentation showcases/illustrates the results of this study as well as demonstrating other features/capabilities of the RSMoX system. Learning Objectives: Understand the importance of comprehensive, non-invasive physiological monitoring – including oxygen saturation – for reproducible animal research outcomes. Learn about the new features of the redesigned Rodent Surgical Monitoring Platform]]> Thu, 29 May 2025 19:00:58 GMT /slideshow/an-efficient-and-reliable-method-to-determine-spo2-in-rodents-pdf/279882978 scinticasam@slideshare.net(scinticasam) An Efficient and Reliable Method to Determine SpO2 in Rodents.pdf scinticasam Accurate, non-invasive physiological monitoring is key to reproducible pre-clinical research studies. While the Rodent Surgical Monitor (RSM+) system has helped many researchers monitor the standard vital signs ECG, respiration, and core temperature in their experimental animals, oxygen saturation – a critical clinical parameter – has often been overlooked or under utilized. Now, a newly launched platform changes that. Featuring patent-pending ECG electrodes with integrated pulse oximetry sensors on the platform with redesigned electronics for cleaner, more reliable data, this next-generation system sets a new standard for precision monitoring during procedures. Clinically, oxygen saturation or SpO2 measurements are made routinely because it directly reflects upon how effectively oxygen is being transported via the blood from the lungs to the entire body. It is a key indicator of respiratory and cardiovascular function used to monitor patients while under anesthesia, confirm and assess respiratory or cardiac conditions, etc. Accurate oxygen saturation monitoring can help prevent organ damage, improve patient outcomes, and support timely clinical interventions. Even though used extensively clinically, oxygen saturation has not been routinely measured in preclinical studies. However, with changing perceptions to increase monitoring and reproducibility of studies, researchers have started to opt for this measurement. The Indus Instruments RSM+ system has a commercially available external thigh clip sensor for SpO2 measurement. However, clip SpO2 sensors depend on proper placement at the desired physical location on the animal (thigh, paw, tail, etc.), proper orientation to minimize respiration artifact, and the need to shave hair at the site of measurement are some of the key requirements. To mitigate and/or minimize these issues, Indus Instruments now offers a newly launched platform (RSMoX) that offers pulse oximetry sensors integrated into ECG electrodes that will detect oxygen saturation in the paw in either mice or rats, greatly reducing placement time and improving the reliability and reproducibility of SpO2 measurements. Oxygen saturation measurements were obtained from the paw with RSMoX system were compared to and validated with the commercially available, Indus external thigh clip sensor and StarrLife (Mouse Ox) thigh clip sensor at baseline (normoxia) and during hypoxia induced using nitrogen gas. The results demonstrated no significant differences between the measurements of the ECG electrode paw sensor versus the clip sensors. The following presentation showcases/illustrates the results of this study as well as demonstrating other features/capabilities of the RSMoX system. Learning Objectives: Understand the importance of comprehensive, non-invasive physiological monitoring – including oxygen saturation – for reproducible animal research outcomes. Learn about the new features of the redesigned Rodent Surgical Monitoring Platform <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/slides-anefficientandreliablemethodtodeterminespo2inrodents-250529190059-482650b8-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Accurate, non-invasive physiological monitoring is key to reproducible pre-clinical research studies. While the Rodent Surgical Monitor (RSM+) system has helped many researchers monitor the standard vital signs ECG, respiration, and core temperature in their experimental animals, oxygen saturation – a critical clinical parameter – has often been overlooked or under utilized. Now, a newly launched platform changes that. Featuring patent-pending ECG electrodes with integrated pulse oximetry sensors on the platform with redesigned electronics for cleaner, more reliable data, this next-generation system sets a new standard for precision monitoring during procedures. Clinically, oxygen saturation or SpO2 measurements are made routinely because it directly reflects upon how effectively oxygen is being transported via the blood from the lungs to the entire body. It is a key indicator of respiratory and cardiovascular function used to monitor patients while under anesthesia, confirm and assess respiratory or cardiac conditions, etc. Accurate oxygen saturation monitoring can help prevent organ damage, improve patient outcomes, and support timely clinical interventions. Even though used extensively clinically, oxygen saturation has not been routinely measured in preclinical studies. However, with changing perceptions to increase monitoring and reproducibility of studies, researchers have started to opt for this measurement. The Indus Instruments RSM+ system has a commercially available external thigh clip sensor for SpO2 measurement. However, clip SpO2 sensors depend on proper placement at the desired physical location on the animal (thigh, paw, tail, etc.), proper orientation to minimize respiration artifact, and the need to shave hair at the site of measurement are some of the key requirements. To mitigate and/or minimize these issues, Indus Instruments now offers a newly launched platform (RSMoX) that offers pulse oximetry sensors integrated into ECG electrodes that will detect oxygen saturation in the paw in either mice or rats, greatly reducing placement time and improving the reliability and reproducibility of SpO2 measurements. Oxygen saturation measurements were obtained from the paw with RSMoX system were compared to and validated with the commercially available, Indus external thigh clip sensor and StarrLife (Mouse Ox) thigh clip sensor at baseline (normoxia) and during hypoxia induced using nitrogen gas. The results demonstrated no significant differences between the measurements of the ECG electrode paw sensor versus the clip sensors. The following presentation showcases/illustrates the results of this study as well as demonstrating other features/capabilities of the RSMoX system. Learning Objectives: Understand the importance of comprehensive, non-invasive physiological monitoring – including oxygen saturation – for reproducible animal research outcomes. Learn about the new features of the redesigned Rodent Surgical Monitoring Platform
An Efficient and Reliable Method to Determine SpO2 in Rodents.pdf from Scintica Instrumentation
]]> 119 0 https://cdn.slidesharecdn.com/ss_thumbnails/slides-anefficientandreliablemethodtodeterminespo2inrodents-250529190059-482650b8-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Witness the Power of Contrast Agents & Multimodal Imaging: MRI, Ultrasound, CT, Optical /slideshow/witness-the-power-of-contrast-agents-multimodal-imaging-mri-ultrasound-ct-optical/276610442 20250306viscoverscinticawebinar1-250312135555-6be7754a
Contrast agents play a crucial role in advancing research and medicine by enhancing the clarity and detail of imaging modalities such as MRI, ultrasound, CT, and optical imaging. These agents improve the visualization of tissues, blood vessels, and pathological processes, enabling more accurate diagnosis and treatment planning. In MRI, contrast agents highlight soft tissue differences, while in CT, they enhance the visibility of vascular structures and organs. Ultrasound contrast agents improve blood flow imaging, and optical agents enable real-time molecular imaging. By providing precise, non-invasive insights into complex biological systems, contrast agents are revolutionizing disease detection, therapy monitoring, and personalized medicine. Understand the role and applications of contrast agents in enhancing imaging modalities, including MRI, CT, ultrasound, and optical imaging, for preclinical and clinical research. Analyze the specific use of gadolinium-based contrast agents in MRI for studying brain waste clearance mechanisms and their relevance to Alzheimer's disease research. Explore the application of CT contrast agents in oncological drug development, focusing on tumor vascularization, drug delivery, and therapeutic response. Evaluate the integration of MRI, CT, ultrasound, and optical imaging with contrast agents in comprehensive diabetes studies Examine the synergistic potential of Viscover’s contrast agents and Scintica's imaging systems in advancing preclinical research and translational medicine. Contrast agents are indispensable tools in preclinical and clinical research, enabling precise visualization and detailed analysis across multiple imaging modalities, including magnetic resonance imaging (MRI), ultrasound, computed tomography (CT), and optical imaging. These agents enhance the contrast between tissues, making subtle biological processes and structural changes visible. In MRI, gadolinium-based contrast agents are pivotal for brain waste clearance studies, such as those investigating the glymphatic system's role in clearing toxic proteins linked to Alzheimer's disease. CT contrast agents are instrumental in oncological drug development, allowing researchers to assess tumor vascularity, drug delivery efficiency, and therapeutic response. Diabetes studies benefit from a multifaceted approach combining MRI, ultrasound, CT, and optical imaging, each with targeted contrast agents to evaluate tissue perfusion, pancreatic function, vascular changes, and metabolic processes. Together, these modalities bridge the gap between preclinical discoveries and clinical applications, embodying the principles of translational medicine by fostering a comprehensive understanding of diseases and their treatment. Viscover, developed by nanoPET Pharma GmbH, offers a comprehensive portfolio of specialized imaging agents designed for preclinical small animal studies across various modalities, including MRI, CT, ultrasound, and optical imaging]]>
Contrast agents play a crucial role in advancing research and medicine by enhancing the clarity and detail of imaging modalities such as MRI, ultrasound, CT, and optical imaging. These agents improve the visualization of tissues, blood vessels, and pathological processes, enabling more accurate diagnosis and treatment planning. In MRI, contrast agents highlight soft tissue differences, while in CT, they enhance the visibility of vascular structures and organs. Ultrasound contrast agents improve blood flow imaging, and optical agents enable real-time molecular imaging. By providing precise, non-invasive insights into complex biological systems, contrast agents are revolutionizing disease detection, therapy monitoring, and personalized medicine. Understand the role and applications of contrast agents in enhancing imaging modalities, including MRI, CT, ultrasound, and optical imaging, for preclinical and clinical research. Analyze the specific use of gadolinium-based contrast agents in MRI for studying brain waste clearance mechanisms and their relevance to Alzheimer's disease research. Explore the application of CT contrast agents in oncological drug development, focusing on tumor vascularization, drug delivery, and therapeutic response. Evaluate the integration of MRI, CT, ultrasound, and optical imaging with contrast agents in comprehensive diabetes studies Examine the synergistic potential of Viscover’s contrast agents and Scintica's imaging systems in advancing preclinical research and translational medicine. Contrast agents are indispensable tools in preclinical and clinical research, enabling precise visualization and detailed analysis across multiple imaging modalities, including magnetic resonance imaging (MRI), ultrasound, computed tomography (CT), and optical imaging. These agents enhance the contrast between tissues, making subtle biological processes and structural changes visible. In MRI, gadolinium-based contrast agents are pivotal for brain waste clearance studies, such as those investigating the glymphatic system's role in clearing toxic proteins linked to Alzheimer's disease. CT contrast agents are instrumental in oncological drug development, allowing researchers to assess tumor vascularity, drug delivery efficiency, and therapeutic response. Diabetes studies benefit from a multifaceted approach combining MRI, ultrasound, CT, and optical imaging, each with targeted contrast agents to evaluate tissue perfusion, pancreatic function, vascular changes, and metabolic processes. Together, these modalities bridge the gap between preclinical discoveries and clinical applications, embodying the principles of translational medicine by fostering a comprehensive understanding of diseases and their treatment. Viscover, developed by nanoPET Pharma GmbH, offers a comprehensive portfolio of specialized imaging agents designed for preclinical small animal studies across various modalities, including MRI, CT, ultrasound, and optical imaging]]> Wed, 12 Mar 2025 13:55:55 GMT /slideshow/witness-the-power-of-contrast-agents-multimodal-imaging-mri-ultrasound-ct-optical/276610442 scinticasam@slideshare.net(scinticasam) Witness the Power of Contrast Agents & Multimodal Imaging: MRI, Ultrasound, CT, Optical scinticasam Contrast agents play a crucial role in advancing research and medicine by enhancing the clarity and detail of imaging modalities such as MRI, ultrasound, CT, and optical imaging. These agents improve the visualization of tissues, blood vessels, and pathological processes, enabling more accurate diagnosis and treatment planning. In MRI, contrast agents highlight soft tissue differences, while in CT, they enhance the visibility of vascular structures and organs. Ultrasound contrast agents improve blood flow imaging, and optical agents enable real-time molecular imaging. By providing precise, non-invasive insights into complex biological systems, contrast agents are revolutionizing disease detection, therapy monitoring, and personalized medicine. Understand the role and applications of contrast agents in enhancing imaging modalities, including MRI, CT, ultrasound, and optical imaging, for preclinical and clinical research. Analyze the specific use of gadolinium-based contrast agents in MRI for studying brain waste clearance mechanisms and their relevance to Alzheimer's disease research. Explore the application of CT contrast agents in oncological drug development, focusing on tumor vascularization, drug delivery, and therapeutic response. Evaluate the integration of MRI, CT, ultrasound, and optical imaging with contrast agents in comprehensive diabetes studies Examine the synergistic potential of Viscover’s contrast agents and Scintica's imaging systems in advancing preclinical research and translational medicine. Contrast agents are indispensable tools in preclinical and clinical research, enabling precise visualization and detailed analysis across multiple imaging modalities, including magnetic resonance imaging (MRI), ultrasound, computed tomography (CT), and optical imaging. These agents enhance the contrast between tissues, making subtle biological processes and structural changes visible. In MRI, gadolinium-based contrast agents are pivotal for brain waste clearance studies, such as those investigating the glymphatic system's role in clearing toxic proteins linked to Alzheimer's disease. CT contrast agents are instrumental in oncological drug development, allowing researchers to assess tumor vascularity, drug delivery efficiency, and therapeutic response. Diabetes studies benefit from a multifaceted approach combining MRI, ultrasound, CT, and optical imaging, each with targeted contrast agents to evaluate tissue perfusion, pancreatic function, vascular changes, and metabolic processes. Together, these modalities bridge the gap between preclinical discoveries and clinical applications, embodying the principles of translational medicine by fostering a comprehensive understanding of diseases and their treatment. Viscover, developed by nanoPET Pharma GmbH, offers a comprehensive portfolio of specialized imaging agents designed for preclinical small animal studies across various modalities, including MRI, CT, ultrasound, and optical imaging <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/20250306viscoverscinticawebinar1-250312135555-6be7754a-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Contrast agents play a crucial role in advancing research and medicine by enhancing the clarity and detail of imaging modalities such as MRI, ultrasound, CT, and optical imaging. These agents improve the visualization of tissues, blood vessels, and pathological processes, enabling more accurate diagnosis and treatment planning. In MRI, contrast agents highlight soft tissue differences, while in CT, they enhance the visibility of vascular structures and organs. Ultrasound contrast agents improve blood flow imaging, and optical agents enable real-time molecular imaging. By providing precise, non-invasive insights into complex biological systems, contrast agents are revolutionizing disease detection, therapy monitoring, and personalized medicine. Understand the role and applications of contrast agents in enhancing imaging modalities, including MRI, CT, ultrasound, and optical imaging, for preclinical and clinical research. Analyze the specific use of gadolinium-based contrast agents in MRI for studying brain waste clearance mechanisms and their relevance to Alzheimer&#39;s disease research. Explore the application of CT contrast agents in oncological drug development, focusing on tumor vascularization, drug delivery, and therapeutic response. Evaluate the integration of MRI, CT, ultrasound, and optical imaging with contrast agents in comprehensive diabetes studies Examine the synergistic potential of Viscover’s contrast agents and Scintica&#39;s imaging systems in advancing preclinical research and translational medicine. Contrast agents are indispensable tools in preclinical and clinical research, enabling precise visualization and detailed analysis across multiple imaging modalities, including magnetic resonance imaging (MRI), ultrasound, computed tomography (CT), and optical imaging. These agents enhance the contrast between tissues, making subtle biological processes and structural changes visible. In MRI, gadolinium-based contrast agents are pivotal for brain waste clearance studies, such as those investigating the glymphatic system&#39;s role in clearing toxic proteins linked to Alzheimer&#39;s disease. CT contrast agents are instrumental in oncological drug development, allowing researchers to assess tumor vascularity, drug delivery efficiency, and therapeutic response. Diabetes studies benefit from a multifaceted approach combining MRI, ultrasound, CT, and optical imaging, each with targeted contrast agents to evaluate tissue perfusion, pancreatic function, vascular changes, and metabolic processes. Together, these modalities bridge the gap between preclinical discoveries and clinical applications, embodying the principles of translational medicine by fostering a comprehensive understanding of diseases and their treatment. Viscover, developed by nanoPET Pharma GmbH, offers a comprehensive portfolio of specialized imaging agents designed for preclinical small animal studies across various modalities, including MRI, CT, ultrasound, and optical imaging
Witness the Power of Contrast Agents & Multimodal Imaging: MRI, Ultrasound, CT, Optical from Scintica Instrumentation
]]> 168 0 https://cdn.slidesharecdn.com/ss_thumbnails/20250306viscoverscinticawebinar1-250312135555-6be7754a-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 (February 25th, 2025) Real-Time Insights into Cardiothoracic Research with Intravital Microscopy /slideshow/february-25th-2025-real-time-insights-into-cardiothoracic-research-with-intravital-microscopy/276054763 cardiothoracicwebinarfeb2025-250226161727-7df2413b
s a major gap - these methods can't fully capture how cells behave in a living, breathing system. That's where Intravital Microscopy (IVM) comes in. This powerful imaging technology allows researchers to see cellular activity in real-time, with incredible clarity and precision. But imaging the heart and lungs presents a unique challenge. These organs are constantly in motion, making real-time visualization tricky. Thankfully, groundbreaking advances - like vacuum-based stabilization and motion compensation algorithms - are making high-resolution imaging of these moving structures a reality. What You'll Gain from This Webinar: - New Scientific Insights – See how IVM is transforming our understanding of immune cell movement in the lungs, cellular changes in heart disease, and more. - Advanced Imaging Solutions – Discover the latest stabilization techniques that make it possible to capture clear, detailed images of beating hearts and expanding lungs. - Real-World Applications – Learn how these innovations are driving major breakthroughs in cardiovascular and pulmonary research, with direct implications for disease treatment and drug development. - Live Expert Discussion – Connect with experts and get answers to your biggest questions about in vivo imaging. This is your chance to explore how cutting-edge imaging is revolutionizing cardiothoracic research - shedding light on disease mechanisms, immune responses, and new therapeutic possibilities. - Register now and stay ahead of the curve in in vivo imaging!]]>
s a major gap - these methods can't fully capture how cells behave in a living, breathing system. That's where Intravital Microscopy (IVM) comes in. This powerful imaging technology allows researchers to see cellular activity in real-time, with incredible clarity and precision. But imaging the heart and lungs presents a unique challenge. These organs are constantly in motion, making real-time visualization tricky. Thankfully, groundbreaking advances - like vacuum-based stabilization and motion compensation algorithms - are making high-resolution imaging of these moving structures a reality. What You'll Gain from This Webinar: - New Scientific Insights – See how IVM is transforming our understanding of immune cell movement in the lungs, cellular changes in heart disease, and more. - Advanced Imaging Solutions – Discover the latest stabilization techniques that make it possible to capture clear, detailed images of beating hearts and expanding lungs. - Real-World Applications – Learn how these innovations are driving major breakthroughs in cardiovascular and pulmonary research, with direct implications for disease treatment and drug development. - Live Expert Discussion – Connect with experts and get answers to your biggest questions about in vivo imaging. This is your chance to explore how cutting-edge imaging is revolutionizing cardiothoracic research - shedding light on disease mechanisms, immune responses, and new therapeutic possibilities. - Register now and stay ahead of the curve in in vivo imaging!]]> Wed, 26 Feb 2025 16:17:27 GMT /slideshow/february-25th-2025-real-time-insights-into-cardiothoracic-research-with-intravital-microscopy/276054763 scinticasam@slideshare.net(scinticasam) (February 25th, 2025) Real-Time Insights into Cardiothoracic Research with Intravital Microscopy scinticasam s a major gap - these methods can't fully capture how cells behave in a living, breathing system. That's where Intravital Microscopy (IVM) comes in. This powerful imaging technology allows researchers to see cellular activity in real-time, with incredible clarity and precision. But imaging the heart and lungs presents a unique challenge. These organs are constantly in motion, making real-time visualization tricky. Thankfully, groundbreaking advances - like vacuum-based stabilization and motion compensation algorithms - are making high-resolution imaging of these moving structures a reality. What You'll Gain from This Webinar: - New Scientific Insights – See how IVM is transforming our understanding of immune cell movement in the lungs, cellular changes in heart disease, and more. - Advanced Imaging Solutions – Discover the latest stabilization techniques that make it possible to capture clear, detailed images of beating hearts and expanding lungs. - Real-World Applications – Learn how these innovations are driving major breakthroughs in cardiovascular and pulmonary research, with direct implications for disease treatment and drug development. - Live Expert Discussion – Connect with experts and get answers to your biggest questions about in vivo imaging. This is your chance to explore how cutting-edge imaging is revolutionizing cardiothoracic research - shedding light on disease mechanisms, immune responses, and new therapeutic possibilities. - Register now and stay ahead of the curve in in vivo imaging! <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/cardiothoracicwebinarfeb2025-250226161727-7df2413b-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> s a major gap - these methods can&#39;t fully capture how cells behave in a living, breathing system. That&#39;s where Intravital Microscopy (IVM) comes in. This powerful imaging technology allows researchers to see cellular activity in real-time, with incredible clarity and precision. But imaging the heart and lungs presents a unique challenge. These organs are constantly in motion, making real-time visualization tricky. Thankfully, groundbreaking advances - like vacuum-based stabilization and motion compensation algorithms - are making high-resolution imaging of these moving structures a reality. What You&#39;ll Gain from This Webinar: - New Scientific Insights – See how IVM is transforming our understanding of immune cell movement in the lungs, cellular changes in heart disease, and more. - Advanced Imaging Solutions – Discover the latest stabilization techniques that make it possible to capture clear, detailed images of beating hearts and expanding lungs. - Real-World Applications – Learn how these innovations are driving major breakthroughs in cardiovascular and pulmonary research, with direct implications for disease treatment and drug development. - Live Expert Discussion – Connect with experts and get answers to your biggest questions about in vivo imaging. This is your chance to explore how cutting-edge imaging is revolutionizing cardiothoracic research - shedding light on disease mechanisms, immune responses, and new therapeutic possibilities. - Register now and stay ahead of the curve in in vivo imaging!
(February 25th, 2025) Real-Time Insights into Cardiothoracic Research with Intravital Microscopy from Scintica Instrumentation
]]> 95 0 https://cdn.slidesharecdn.com/ss_thumbnails/cardiothoracicwebinarfeb2025-250226161727-7df2413b-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 iNSiGHT DXA : Live Virtual Demonstration /slideshow/insight-dxa-live-virtual-demonstration/276022808 insightdxa-livedemo-250225162132-8a88d3c0
Live Virtual Demo: iNSiGHT DEXA Imaging System Attendees joined us for an interactive live demo of the iNSiGHT DEXA imaging system—a powerful tool for preclinical body composition and bone mineral density analysis. They saw firsthand how it delivered precise and efficient measurements (FAST 25 seconds) to advance their research. What Was Covered: Our expert team guided participants through a hands-on demonstration, including: Accurate fat/lean composition & bone density analysis in mice and ex vivo samples Flexible region-of-interest (ROI) tools for customized analysis User-friendly software that streamlined data acquisition and boosted productivity Key Takeaways: Conducting body composition and bone density analysis with confidence Optimizing workflows with intuitive software tools Simplifying data acquisition without compromising precision Whether attendees were new to DEXA or refining their techniques, this session provided practical insights to enhance their preclinical research.]]>
Live Virtual Demo: iNSiGHT DEXA Imaging System Attendees joined us for an interactive live demo of the iNSiGHT DEXA imaging system—a powerful tool for preclinical body composition and bone mineral density analysis. They saw firsthand how it delivered precise and efficient measurements (FAST 25 seconds) to advance their research. What Was Covered: Our expert team guided participants through a hands-on demonstration, including: Accurate fat/lean composition & bone density analysis in mice and ex vivo samples Flexible region-of-interest (ROI) tools for customized analysis User-friendly software that streamlined data acquisition and boosted productivity Key Takeaways: Conducting body composition and bone density analysis with confidence Optimizing workflows with intuitive software tools Simplifying data acquisition without compromising precision Whether attendees were new to DEXA or refining their techniques, this session provided practical insights to enhance their preclinical research.]]> Tue, 25 Feb 2025 16:21:32 GMT /slideshow/insight-dxa-live-virtual-demonstration/276022808 scinticasam@slideshare.net(scinticasam) iNSiGHT DXA : Live Virtual Demonstration scinticasam Live Virtual Demo: iNSiGHT DEXA Imaging System Attendees joined us for an interactive live demo of the iNSiGHT DEXA imaging system—a powerful tool for preclinical body composition and bone mineral density analysis. They saw firsthand how it delivered precise and efficient measurements (FAST 25 seconds) to advance their research. What Was Covered: Our expert team guided participants through a hands-on demonstration, including: Accurate fat/lean composition & bone density analysis in mice and ex vivo samples Flexible region-of-interest (ROI) tools for customized analysis User-friendly software that streamlined data acquisition and boosted productivity Key Takeaways: Conducting body composition and bone density analysis with confidence Optimizing workflows with intuitive software tools Simplifying data acquisition without compromising precision Whether attendees were new to DEXA or refining their techniques, this session provided practical insights to enhance their preclinical research. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/insightdxa-livedemo-250225162132-8a88d3c0-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Live Virtual Demo: iNSiGHT DEXA Imaging System Attendees joined us for an interactive live demo of the iNSiGHT DEXA imaging system—a powerful tool for preclinical body composition and bone mineral density analysis. They saw firsthand how it delivered precise and efficient measurements (FAST 25 seconds) to advance their research. What Was Covered: Our expert team guided participants through a hands-on demonstration, including: Accurate fat/lean composition &amp; bone density analysis in mice and ex vivo samples Flexible region-of-interest (ROI) tools for customized analysis User-friendly software that streamlined data acquisition and boosted productivity Key Takeaways: Conducting body composition and bone density analysis with confidence Optimizing workflows with intuitive software tools Simplifying data acquisition without compromising precision Whether attendees were new to DEXA or refining their techniques, this session provided practical insights to enhance their preclinical research.
iNSiGHT DXA : Live Virtual Demonstration from Scintica Instrumentation
]]> 17 0 https://cdn.slidesharecdn.com/ss_thumbnails/insightdxa-livedemo-250225162132-8a88d3c0-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 The Paradigm Shift from Normoxia to Physoxia: Enhancing Experimental Precision for Better Translational Outcomes /slideshow/the-paradigm-shift-from-normoxia-to-physoxia-enhancing-experimental-precision-for-better-translational-outcomes/274043827 slidedeckforscinticafordistribution-oaandhypoxiabydrrantanen-241213184253-e965d3e6
The overarching aim of this webinar is to facilitate understanding of the role oxygen plays in biological processes. This is fundamental in developing precise experimental models that mimic human biology, and it will help develop improved future translational outcomes. This impacts the core value of investment in medical research and will help attendees position themselves better in the field. The attendees will gain understanding on how broadly experimental setup have to factor in different aspects in the cellular environment in order for the produced data to be translational and reproducible. We will go through what/how molecular mechanisms respond to different oxygen levels and what impact this has on a given system. The lecture will increase awareness about oxygen’s effects in different fields of biology, be it cancer research, stem cell biology, plant biology, drug discovery, materials science etc. Specific attention will be given on chondrocyte biology and how different oxygen levels affect orthopaedic research. In addition, attendees will gain insight on how oxygen levels can be controlled in an experimental setting from a technical perspective.]]>
The overarching aim of this webinar is to facilitate understanding of the role oxygen plays in biological processes. This is fundamental in developing precise experimental models that mimic human biology, and it will help develop improved future translational outcomes. This impacts the core value of investment in medical research and will help attendees position themselves better in the field. The attendees will gain understanding on how broadly experimental setup have to factor in different aspects in the cellular environment in order for the produced data to be translational and reproducible. We will go through what/how molecular mechanisms respond to different oxygen levels and what impact this has on a given system. The lecture will increase awareness about oxygen’s effects in different fields of biology, be it cancer research, stem cell biology, plant biology, drug discovery, materials science etc. Specific attention will be given on chondrocyte biology and how different oxygen levels affect orthopaedic research. In addition, attendees will gain insight on how oxygen levels can be controlled in an experimental setting from a technical perspective.]]> Fri, 13 Dec 2024 18:42:53 GMT /slideshow/the-paradigm-shift-from-normoxia-to-physoxia-enhancing-experimental-precision-for-better-translational-outcomes/274043827 scinticasam@slideshare.net(scinticasam) The Paradigm Shift from Normoxia to Physoxia: Enhancing Experimental Precision for Better Translational Outcomes scinticasam The overarching aim of this webinar is to facilitate understanding of the role oxygen plays in biological processes. This is fundamental in developing precise experimental models that mimic human biology, and it will help develop improved future translational outcomes. This impacts the core value of investment in medical research and will help attendees position themselves better in the field. The attendees will gain understanding on how broadly experimental setup have to factor in different aspects in the cellular environment in order for the produced data to be translational and reproducible. We will go through what/how molecular mechanisms respond to different oxygen levels and what impact this has on a given system. The lecture will increase awareness about oxygen’s effects in different fields of biology, be it cancer research, stem cell biology, plant biology, drug discovery, materials science etc. Specific attention will be given on chondrocyte biology and how different oxygen levels affect orthopaedic research. In addition, attendees will gain insight on how oxygen levels can be controlled in an experimental setting from a technical perspective. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/slidedeckforscinticafordistribution-oaandhypoxiabydrrantanen-241213184253-e965d3e6-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> The overarching aim of this webinar is to facilitate understanding of the role oxygen plays in biological processes. This is fundamental in developing precise experimental models that mimic human biology, and it will help develop improved future translational outcomes. This impacts the core value of investment in medical research and will help attendees position themselves better in the field. The attendees will gain understanding on how broadly experimental setup have to factor in different aspects in the cellular environment in order for the produced data to be translational and reproducible. We will go through what/how molecular mechanisms respond to different oxygen levels and what impact this has on a given system. The lecture will increase awareness about oxygen’s effects in different fields of biology, be it cancer research, stem cell biology, plant biology, drug discovery, materials science etc. Specific attention will be given on chondrocyte biology and how different oxygen levels affect orthopaedic research. In addition, attendees will gain insight on how oxygen levels can be controlled in an experimental setting from a technical perspective.
The Paradigm Shift from Normoxia to Physoxia: Enhancing Experimental Precision for Better Translational Outcomes from Scintica Instrumentation
]]> 46 0 https://cdn.slidesharecdn.com/ss_thumbnails/slidedeckforscinticafordistribution-oaandhypoxiabydrrantanen-241213184253-e965d3e6-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 (November 14, 2024) NIR-II Fluorescence imaging: Why, When and How /slideshow/november-14-2024-nir-ii-fluorescence-imaging-why-when-and-how/273314552 vilbernewton7-241114194009-87e80168
Short-Wave Infrared (SWIR) Imaging, also known as NIR-II imaging, operates in the 900–2000 nm wavelength range and represents a significant advancement for in vivo preclinical applications. This imaging method offers numerous advantages over traditional VIS/NIR imaging, thanks to its unique optical properties, which allow for deeper tissue penetration, reduced autofluorescence, enhanced image clarity, and an improved signal-to-noise ratio. NIR-II imaging provides highly detailed insights into vascular blood flow, drug dispersion in metabolic studies, tumor targeting, tumor angiogenesis, brain tumors, and even single-cell imaging. In this webinar, discover Vilber Bio Imaging’s latest NIR-II imaging technology for small animals—the NEWTON FT-900. This powerful, versatile imager combines dual-camera SWIR imaging capabilities with traditional Bioluminescence and VIS/NIR Fluorescence imaging, delivering a comprehensive imaging solution in one device. Learning Objectives for Attendees: - Understand the advantages of NIR-II in vivo imaging compared to traditional imaging techniques - Explore key in vivo applications for SWIR imaging - Gain a technical overview of the Newton FT-900]]>
Short-Wave Infrared (SWIR) Imaging, also known as NIR-II imaging, operates in the 900–2000 nm wavelength range and represents a significant advancement for in vivo preclinical applications. This imaging method offers numerous advantages over traditional VIS/NIR imaging, thanks to its unique optical properties, which allow for deeper tissue penetration, reduced autofluorescence, enhanced image clarity, and an improved signal-to-noise ratio. NIR-II imaging provides highly detailed insights into vascular blood flow, drug dispersion in metabolic studies, tumor targeting, tumor angiogenesis, brain tumors, and even single-cell imaging. In this webinar, discover Vilber Bio Imaging’s latest NIR-II imaging technology for small animals—the NEWTON FT-900. This powerful, versatile imager combines dual-camera SWIR imaging capabilities with traditional Bioluminescence and VIS/NIR Fluorescence imaging, delivering a comprehensive imaging solution in one device. Learning Objectives for Attendees: - Understand the advantages of NIR-II in vivo imaging compared to traditional imaging techniques - Explore key in vivo applications for SWIR imaging - Gain a technical overview of the Newton FT-900]]> Thu, 14 Nov 2024 19:40:09 GMT /slideshow/november-14-2024-nir-ii-fluorescence-imaging-why-when-and-how/273314552 scinticasam@slideshare.net(scinticasam) (November 14, 2024) NIR-II Fluorescence imaging: Why, When and How scinticasam Short-Wave Infrared (SWIR) Imaging, also known as NIR-II imaging, operates in the 900–2000 nm wavelength range and represents a significant advancement for in vivo preclinical applications. This imaging method offers numerous advantages over traditional VIS/NIR imaging, thanks to its unique optical properties, which allow for deeper tissue penetration, reduced autofluorescence, enhanced image clarity, and an improved signal-to-noise ratio. NIR-II imaging provides highly detailed insights into vascular blood flow, drug dispersion in metabolic studies, tumor targeting, tumor angiogenesis, brain tumors, and even single-cell imaging. In this webinar, discover Vilber Bio Imaging’s latest NIR-II imaging technology for small animals—the NEWTON FT-900. This powerful, versatile imager combines dual-camera SWIR imaging capabilities with traditional Bioluminescence and VIS/NIR Fluorescence imaging, delivering a comprehensive imaging solution in one device. Learning Objectives for Attendees: - Understand the advantages of NIR-II in vivo imaging compared to traditional imaging techniques - Explore key in vivo applications for SWIR imaging - Gain a technical overview of the Newton FT-900 <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/vilbernewton7-241114194009-87e80168-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Short-Wave Infrared (SWIR) Imaging, also known as NIR-II imaging, operates in the 900–2000 nm wavelength range and represents a significant advancement for in vivo preclinical applications. This imaging method offers numerous advantages over traditional VIS/NIR imaging, thanks to its unique optical properties, which allow for deeper tissue penetration, reduced autofluorescence, enhanced image clarity, and an improved signal-to-noise ratio. NIR-II imaging provides highly detailed insights into vascular blood flow, drug dispersion in metabolic studies, tumor targeting, tumor angiogenesis, brain tumors, and even single-cell imaging. In this webinar, discover Vilber Bio Imaging’s latest NIR-II imaging technology for small animals—the NEWTON FT-900. This powerful, versatile imager combines dual-camera SWIR imaging capabilities with traditional Bioluminescence and VIS/NIR Fluorescence imaging, delivering a comprehensive imaging solution in one device. Learning Objectives for Attendees: - Understand the advantages of NIR-II in vivo imaging compared to traditional imaging techniques - Explore key in vivo applications for SWIR imaging - Gain a technical overview of the Newton FT-900
(November 14, 2024) NIR-II Fluorescence imaging: Why, When and How from Scintica Instrumentation
]]> 110 0 https://cdn.slidesharecdn.com/ss_thumbnails/vilbernewton7-241114194009-87e80168-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Reduce and Prevent Contamination in Tissue and Cell Culture Laboratories /slideshow/reduce-and-prevent-contamination-in-tissue-and-cell-culture-laboratories/273283531 nov132024mycofogwebinar-scintica-241113192841-b0d87b20
MycoFog™ is a novel system designed specifically to help tissue and cell culture labs eliminate or reduce contamination events. In this webinar we will describe the details on the use of MycoFog in the laboratory. Previously we have described in general incubator/isolator contaminations and where MycoFog fits in the laboratory’s contamination control program. In this webinar we will describe the preventative use of MycoFog. Learning objectives for the attendees: - MycoFog’s compatibility with various types of incubators, isolators and other laboratory equipment - Which MycoFog reagents are used in which pieces of that equipment. - How to best utilize MycoFog’s ease-of-use in your lab Learn more here: https://scintica.com/product/mycofog-biodecontamination-system/]]>
MycoFog™ is a novel system designed specifically to help tissue and cell culture labs eliminate or reduce contamination events. In this webinar we will describe the details on the use of MycoFog in the laboratory. Previously we have described in general incubator/isolator contaminations and where MycoFog fits in the laboratory’s contamination control program. In this webinar we will describe the preventative use of MycoFog. Learning objectives for the attendees: - MycoFog’s compatibility with various types of incubators, isolators and other laboratory equipment - Which MycoFog reagents are used in which pieces of that equipment. - How to best utilize MycoFog’s ease-of-use in your lab Learn more here: https://scintica.com/product/mycofog-biodecontamination-system/]]> Wed, 13 Nov 2024 19:28:41 GMT /slideshow/reduce-and-prevent-contamination-in-tissue-and-cell-culture-laboratories/273283531 scinticasam@slideshare.net(scinticasam) Reduce and Prevent Contamination in Tissue and Cell Culture Laboratories scinticasam MycoFog™ is a novel system designed specifically to help tissue and cell culture labs eliminate or reduce contamination events. In this webinar we will describe the details on the use of MycoFog in the laboratory. Previously we have described in general incubator/isolator contaminations and where MycoFog fits in the laboratory’s contamination control program. In this webinar we will describe the preventative use of MycoFog. Learning objectives for the attendees: - MycoFog’s compatibility with various types of incubators, isolators and other laboratory equipment - Which MycoFog reagents are used in which pieces of that equipment. - How to best utilize MycoFog’s ease-of-use in your lab Learn more here: https://scintica.com/product/mycofog-biodecontamination-system/ <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/nov132024mycofogwebinar-scintica-241113192841-b0d87b20-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> MycoFog™ is a novel system designed specifically to help tissue and cell culture labs eliminate or reduce contamination events. In this webinar we will describe the details on the use of MycoFog in the laboratory. Previously we have described in general incubator/isolator contaminations and where MycoFog fits in the laboratory’s contamination control program. In this webinar we will describe the preventative use of MycoFog. Learning objectives for the attendees: - MycoFog’s compatibility with various types of incubators, isolators and other laboratory equipment - Which MycoFog reagents are used in which pieces of that equipment. - How to best utilize MycoFog’s ease-of-use in your lab Learn more here: https://scintica.com/product/mycofog-biodecontamination-system/
Reduce and Prevent Contamination in Tissue and Cell Culture Laboratories from Scintica Instrumentation
]]> 92 0 https://cdn.slidesharecdn.com/ss_thumbnails/nov132024mycofogwebinar-scintica-241113192841-b0d87b20-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Next Generation Bioprinting Platform - A Multimodal Approach for Bioprinting of Cartilaginous Multicellular Spheroids and Skin .pdf /slideshow/next-generation-bioprinting-platform-a-multimodal-approach-for-bioprinting-of-cartilaginous-multicellular-spheroids-and-skin-pdf/272190214 nextgenerationbioprintingplatform-amultimodalapproachforbioprintingofcartilaginousmulticellularspher-241004131546-ce762bba
The Next-Generation Bioprinting (NGB) Platform is designed to combine the advantages of Laser-Assisted Bioprinting (LAB) technology—such as high resolution and enhanced cell viability— with other bioprinting technologies like bioextrusion. This integration enables the fabrication of complex multi-cellular 3D constructs. Featuring robotic automation and innovative fluidics devices, the NGB platform enables transition of the bioprinted products from the laboratory to clinic. The commercial NGB-R system is designed for developing bioprinting procedures at the preclinical stage that are translatable to the clinical-ready NGB-C system. This system complies with Good Manufacturing Practices (GMP) for Advanced Therapy Medicinal Products (ATMPs). In this webinar, we will showcase this translation capacity through bioprinting of skin and cartilaginous multicellular spheroids for building larger tissue structures. ]]>
The Next-Generation Bioprinting (NGB) Platform is designed to combine the advantages of Laser-Assisted Bioprinting (LAB) technology—such as high resolution and enhanced cell viability— with other bioprinting technologies like bioextrusion. This integration enables the fabrication of complex multi-cellular 3D constructs. Featuring robotic automation and innovative fluidics devices, the NGB platform enables transition of the bioprinted products from the laboratory to clinic. The commercial NGB-R system is designed for developing bioprinting procedures at the preclinical stage that are translatable to the clinical-ready NGB-C system. This system complies with Good Manufacturing Practices (GMP) for Advanced Therapy Medicinal Products (ATMPs). In this webinar, we will showcase this translation capacity through bioprinting of skin and cartilaginous multicellular spheroids for building larger tissue structures. ]]> Fri, 04 Oct 2024 13:15:46 GMT /slideshow/next-generation-bioprinting-platform-a-multimodal-approach-for-bioprinting-of-cartilaginous-multicellular-spheroids-and-skin-pdf/272190214 scinticasam@slideshare.net(scinticasam) Next Generation Bioprinting Platform - A Multimodal Approach for Bioprinting of Cartilaginous Multicellular Spheroids and Skin .pdf scinticasam The Next-Generation Bioprinting (NGB) Platform is designed to combine the advantages of Laser-Assisted Bioprinting (LAB) technology—such as high resolution and enhanced cell viability— with other bioprinting technologies like bioextrusion. This integration enables the fabrication of complex multi-cellular 3D constructs. Featuring robotic automation and innovative fluidics devices, the NGB platform enables transition of the bioprinted products from the laboratory to clinic. The commercial NGB-R system is designed for developing bioprinting procedures at the preclinical stage that are translatable to the clinical-ready NGB-C system. This system complies with Good Manufacturing Practices (GMP) for Advanced Therapy Medicinal Products (ATMPs). In this webinar, we will showcase this translation capacity through bioprinting of skin and cartilaginous multicellular spheroids for building larger tissue structures. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/nextgenerationbioprintingplatform-amultimodalapproachforbioprintingofcartilaginousmulticellularspher-241004131546-ce762bba-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> The Next-Generation Bioprinting (NGB) Platform is designed to combine the advantages of Laser-Assisted Bioprinting (LAB) technology—such as high resolution and enhanced cell viability— with other bioprinting technologies like bioextrusion. This integration enables the fabrication of complex multi-cellular 3D constructs. Featuring robotic automation and innovative fluidics devices, the NGB platform enables transition of the bioprinted products from the laboratory to clinic. The commercial NGB-R system is designed for developing bioprinting procedures at the preclinical stage that are translatable to the clinical-ready NGB-C system. This system complies with Good Manufacturing Practices (GMP) for Advanced Therapy Medicinal Products (ATMPs). In this webinar, we will showcase this translation capacity through bioprinting of skin and cartilaginous multicellular spheroids for building larger tissue structures.
Next Generation Bioprinting Platform - A Multimodal Approach for Bioprinting of Cartilaginous Multicellular Spheroids and Skin .pdf from Scintica Instrumentation
]]> 201 0 https://cdn.slidesharecdn.com/ss_thumbnails/nextgenerationbioprintingplatform-amultimodalapproachforbioprintingofcartilaginousmulticellularspher-241004131546-ce762bba-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Gamma Eye calibration, system characterization, and in vivo imaging of 225Ac /slideshow/gamma-eye-calibration-system-characterization-and-in-vivo-imaging-of-225ac/271994101 scinticaratiotxgammaeyewebinarfinal2-240924141724-b3ac5016
Alpha-emitting radiopharmaceutical therapy (aRPT) has garnered increasing interest in recent years as the short path length and double DNA strand breaking power of alpha particles have the potential to kill tumor cells more effectively and selectively than beta-emitting radioisotopes. Actinium-225 has especially gained attention as a potentially powerful therapeutic radioisotope due to several alpha-emissions in its decay chain, giving it the potential to deliver more cytotoxic dose to tumor cells than other alpha-emitters. An unfortunate caveat to 225Ac’s tumor-killing potential is that the low administered activities in both animal models and humans limit the number of gamma rays available for imaging. The relatively low abundance of gamma rays and complex decay scheme of 225Ac, including scatter from multiple high-energy particles, further complicates 225Ac imaging. Conversely, the multiple imageable photon peaks at 440 keV (from 213Bi), 218 keV (from 221Fr), and 80-90 keV (from 213Bi, 209Tl) offer the potential to inform if and how 225Ac and its daughters accumulate differently in the body which is important for dosimetry estimates. Further, imaging of gammas resulting from aRPT administration provides the most direct information on biodistribution. Therefore, despite its challenges, the potential information gain from 225Ac imaging makes it a worthwhile field for research & development. In this webinar, 225Ac imaging with the Gamma Eye is explored. Calibration and system characterization procedures are described. In vivo imaging of [225Ac]DOTATATE in mice is performed at 1, 4, and 96 hours. Image data are reviewed qualitatively and quantitatively. Further, comparisons are made to in vivo imaging and cut-and-count biodistribution of [177Lu]DOTATATE. The results of this preliminary evaluation are encouraging; further testing is warranted. Key takeaways: The Gamma Eye was successfully calibrated to enable 225Ac imaging. In vivo animal imaging enabled visualization of tumors and kidneys across multiple time points and energy windows, including generation of quantitative time-activity curves. While additional characterization is needed, preliminary findings encouraging for use of the Gamma Eye to test novel radiopharmaceuticals quickly and accurately in mice through direct 225Ac imaging. ]]>
Alpha-emitting radiopharmaceutical therapy (aRPT) has garnered increasing interest in recent years as the short path length and double DNA strand breaking power of alpha particles have the potential to kill tumor cells more effectively and selectively than beta-emitting radioisotopes. Actinium-225 has especially gained attention as a potentially powerful therapeutic radioisotope due to several alpha-emissions in its decay chain, giving it the potential to deliver more cytotoxic dose to tumor cells than other alpha-emitters. An unfortunate caveat to 225Ac’s tumor-killing potential is that the low administered activities in both animal models and humans limit the number of gamma rays available for imaging. The relatively low abundance of gamma rays and complex decay scheme of 225Ac, including scatter from multiple high-energy particles, further complicates 225Ac imaging. Conversely, the multiple imageable photon peaks at 440 keV (from 213Bi), 218 keV (from 221Fr), and 80-90 keV (from 213Bi, 209Tl) offer the potential to inform if and how 225Ac and its daughters accumulate differently in the body which is important for dosimetry estimates. Further, imaging of gammas resulting from aRPT administration provides the most direct information on biodistribution. Therefore, despite its challenges, the potential information gain from 225Ac imaging makes it a worthwhile field for research & development. In this webinar, 225Ac imaging with the Gamma Eye is explored. Calibration and system characterization procedures are described. In vivo imaging of [225Ac]DOTATATE in mice is performed at 1, 4, and 96 hours. Image data are reviewed qualitatively and quantitatively. Further, comparisons are made to in vivo imaging and cut-and-count biodistribution of [177Lu]DOTATATE. The results of this preliminary evaluation are encouraging; further testing is warranted. Key takeaways: The Gamma Eye was successfully calibrated to enable 225Ac imaging. In vivo animal imaging enabled visualization of tumors and kidneys across multiple time points and energy windows, including generation of quantitative time-activity curves. While additional characterization is needed, preliminary findings encouraging for use of the Gamma Eye to test novel radiopharmaceuticals quickly and accurately in mice through direct 225Ac imaging. ]]> Tue, 24 Sep 2024 14:17:24 GMT /slideshow/gamma-eye-calibration-system-characterization-and-in-vivo-imaging-of-225ac/271994101 scinticasam@slideshare.net(scinticasam) Gamma Eye calibration, system characterization, and in vivo imaging of 225Ac scinticasam Alpha-emitting radiopharmaceutical therapy (aRPT) has garnered increasing interest in recent years as the short path length and double DNA strand breaking power of alpha particles have the potential to kill tumor cells more effectively and selectively than beta-emitting radioisotopes. Actinium-225 has especially gained attention as a potentially powerful therapeutic radioisotope due to several alpha-emissions in its decay chain, giving it the potential to deliver more cytotoxic dose to tumor cells than other alpha-emitters. An unfortunate caveat to 225Ac’s tumor-killing potential is that the low administered activities in both animal models and humans limit the number of gamma rays available for imaging. The relatively low abundance of gamma rays and complex decay scheme of 225Ac, including scatter from multiple high-energy particles, further complicates 225Ac imaging. Conversely, the multiple imageable photon peaks at 440 keV (from 213Bi), 218 keV (from 221Fr), and 80-90 keV (from 213Bi, 209Tl) offer the potential to inform if and how 225Ac and its daughters accumulate differently in the body which is important for dosimetry estimates. Further, imaging of gammas resulting from aRPT administration provides the most direct information on biodistribution. Therefore, despite its challenges, the potential information gain from 225Ac imaging makes it a worthwhile field for research & development. In this webinar, 225Ac imaging with the Gamma Eye is explored. Calibration and system characterization procedures are described. In vivo imaging of [225Ac]DOTATATE in mice is performed at 1, 4, and 96 hours. Image data are reviewed qualitatively and quantitatively. Further, comparisons are made to in vivo imaging and cut-and-count biodistribution of [177Lu]DOTATATE. The results of this preliminary evaluation are encouraging; further testing is warranted. Key takeaways: The Gamma Eye was successfully calibrated to enable 225Ac imaging. In vivo animal imaging enabled visualization of tumors and kidneys across multiple time points and energy windows, including generation of quantitative time-activity curves. While additional characterization is needed, preliminary findings encouraging for use of the Gamma Eye to test novel radiopharmaceuticals quickly and accurately in mice through direct 225Ac imaging. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/scinticaratiotxgammaeyewebinarfinal2-240924141724-b3ac5016-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Alpha-emitting radiopharmaceutical therapy (aRPT) has garnered increasing interest in recent years as the short path length and double DNA strand breaking power of alpha particles have the potential to kill tumor cells more effectively and selectively than beta-emitting radioisotopes. Actinium-225 has especially gained attention as a potentially powerful therapeutic radioisotope due to several alpha-emissions in its decay chain, giving it the potential to deliver more cytotoxic dose to tumor cells than other alpha-emitters. An unfortunate caveat to 225Ac’s tumor-killing potential is that the low administered activities in both animal models and humans limit the number of gamma rays available for imaging. The relatively low abundance of gamma rays and complex decay scheme of 225Ac, including scatter from multiple high-energy particles, further complicates 225Ac imaging. Conversely, the multiple imageable photon peaks at 440 keV (from 213Bi), 218 keV (from 221Fr), and 80-90 keV (from 213Bi, 209Tl) offer the potential to inform if and how 225Ac and its daughters accumulate differently in the body which is important for dosimetry estimates. Further, imaging of gammas resulting from aRPT administration provides the most direct information on biodistribution. Therefore, despite its challenges, the potential information gain from 225Ac imaging makes it a worthwhile field for research &amp; development. In this webinar, 225Ac imaging with the Gamma Eye is explored. Calibration and system characterization procedures are described. In vivo imaging of [225Ac]DOTATATE in mice is performed at 1, 4, and 96 hours. Image data are reviewed qualitatively and quantitatively. Further, comparisons are made to in vivo imaging and cut-and-count biodistribution of [177Lu]DOTATATE. The results of this preliminary evaluation are encouraging; further testing is warranted. Key takeaways: The Gamma Eye was successfully calibrated to enable 225Ac imaging. In vivo animal imaging enabled visualization of tumors and kidneys across multiple time points and energy windows, including generation of quantitative time-activity curves. While additional characterization is needed, preliminary findings encouraging for use of the Gamma Eye to test novel radiopharmaceuticals quickly and accurately in mice through direct 225Ac imaging.
Gamma Eye calibration, system characterization, and in vivo imaging of 225Ac from Scintica Instrumentation
]]> 240 0 https://cdn.slidesharecdn.com/ss_thumbnails/scinticaratiotxgammaeyewebinarfinal2-240924141724-b3ac5016-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Lab Incubator Decontamination: WHY, WHEN and HOW /slideshow/lab-incubator-decontamination-why-when-and-how/271032181 scintica-webinar-07-2024-mycofog-240815135453-99f98967
Laboratory incubators can get contaminated from many sources, lab air/environment, users’ clothing/hands, or by contaminated cultures introduced into the incubator, etc. Many types of organisms may be involved: bacteria, fungi and viruses. Ever since the introduction of pure cultures, those cultures have been at risk of contamination. For mammalian cell cultures this represents a significant issue since cell lines and cell cultures are slower growing and more fastidious in general than bacterial or fungal cultures. In some cases, the contamination may be obvious. In other cases, especially Mycoplasma sp. contaminations, the primary indication may only be experiments with spurious or nonsensical results. Learning objectives: How undesirable organisms are introduced to an incubator. What to look for when a contamination is suspected. What steps can be taken to minimize contaminations. What actions can be taken when a contamination is confirmed or suspected.]]>
Laboratory incubators can get contaminated from many sources, lab air/environment, users’ clothing/hands, or by contaminated cultures introduced into the incubator, etc. Many types of organisms may be involved: bacteria, fungi and viruses. Ever since the introduction of pure cultures, those cultures have been at risk of contamination. For mammalian cell cultures this represents a significant issue since cell lines and cell cultures are slower growing and more fastidious in general than bacterial or fungal cultures. In some cases, the contamination may be obvious. In other cases, especially Mycoplasma sp. contaminations, the primary indication may only be experiments with spurious or nonsensical results. Learning objectives: How undesirable organisms are introduced to an incubator. What to look for when a contamination is suspected. What steps can be taken to minimize contaminations. What actions can be taken when a contamination is confirmed or suspected.]]> Thu, 15 Aug 2024 13:54:53 GMT /slideshow/lab-incubator-decontamination-why-when-and-how/271032181 scinticasam@slideshare.net(scinticasam) Lab Incubator Decontamination: WHY, WHEN and HOW scinticasam Laboratory incubators can get contaminated from many sources, lab air/environment, users’ clothing/hands, or by contaminated cultures introduced into the incubator, etc. Many types of organisms may be involved: bacteria, fungi and viruses. Ever since the introduction of pure cultures, those cultures have been at risk of contamination. For mammalian cell cultures this represents a significant issue since cell lines and cell cultures are slower growing and more fastidious in general than bacterial or fungal cultures. In some cases, the contamination may be obvious. In other cases, especially Mycoplasma sp. contaminations, the primary indication may only be experiments with spurious or nonsensical results. Learning objectives: How undesirable organisms are introduced to an incubator. What to look for when a contamination is suspected. What steps can be taken to minimize contaminations. What actions can be taken when a contamination is confirmed or suspected. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/scintica-webinar-07-2024-mycofog-240815135453-99f98967-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Laboratory incubators can get contaminated from many sources, lab air/environment, users’ clothing/hands, or by contaminated cultures introduced into the incubator, etc. Many types of organisms may be involved: bacteria, fungi and viruses. Ever since the introduction of pure cultures, those cultures have been at risk of contamination. For mammalian cell cultures this represents a significant issue since cell lines and cell cultures are slower growing and more fastidious in general than bacterial or fungal cultures. In some cases, the contamination may be obvious. In other cases, especially Mycoplasma sp. contaminations, the primary indication may only be experiments with spurious or nonsensical results. Learning objectives: How undesirable organisms are introduced to an incubator. What to look for when a contamination is suspected. What steps can be taken to minimize contaminations. What actions can be taken when a contamination is confirmed or suspected.
Lab Incubator Decontamination: WHY, WHEN and HOW from Scintica Instrumentation
]]> 64 0 https://cdn.slidesharecdn.com/ss_thumbnails/scintica-webinar-07-2024-mycofog-240815135453-99f98967-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 (June 12, 2024) Webinar: Development of PET theranostics targeting the molecular chaperones eHsp90 and HtpG for cancer and infectious disease /slideshow/june-12-2024-webinar-development-of-pet-theranostics-targeting-the-molecular-chaperones-ehsp90-and-htpg-for-cancer-and-infectious-disease/269660721 june12thscinticatalk-240613071945-6dc3bf92
Targeting Hsp90 and its pathogen Orthologs with Tethered Inhibitors as a Diagnostic and Therapeutic Strategy for cancer and infectious diseases with Dr. Timothy Haystead.]]>
Targeting Hsp90 and its pathogen Orthologs with Tethered Inhibitors as a Diagnostic and Therapeutic Strategy for cancer and infectious diseases with Dr. Timothy Haystead.]]> Thu, 13 Jun 2024 07:19:44 GMT /slideshow/june-12-2024-webinar-development-of-pet-theranostics-targeting-the-molecular-chaperones-ehsp90-and-htpg-for-cancer-and-infectious-disease/269660721 scinticasam@slideshare.net(scinticasam) (June 12, 2024) Webinar: Development of PET theranostics targeting the molecular chaperones eHsp90 and HtpG for cancer and infectious disease scinticasam Targeting Hsp90 and its pathogen Orthologs with Tethered Inhibitors as a Diagnostic and Therapeutic Strategy for cancer and infectious diseases with Dr. Timothy Haystead. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/june12thscinticatalk-240613071945-6dc3bf92-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Targeting Hsp90 and its pathogen Orthologs with Tethered Inhibitors as a Diagnostic and Therapeutic Strategy for cancer and infectious diseases with Dr. Timothy Haystead.
(June 12, 2024) Webinar: Development of PET theranostics targeting the molecular chaperones eHsp90 and HtpG for cancer and infectious disease from Scintica Instrumentation
]]> 87 0 https://cdn.slidesharecdn.com/ss_thumbnails/june12thscinticatalk-240613071945-6dc3bf92-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 (May 29th, 2024) Advancements in Intravital Microscopy- Insights for Preclinical Research Applications.pdf /slideshow/may-29th-2024-advancements-in-intravital-microscopy-insights-for-preclinical-research-applications-pdf/269409622 may29th2024advancementsinintravitalmicroscopy-insightsforpreclinicalresearchapplications-240529203050-30a1f29a
Intravital microscopy (IVM) is a powerful tool utilized to study cellular behavior over time and space in vivo. Much of our understanding of cell biology has been accomplished using various in vitro and ex vivo methods; however, these studies do not necessarily reflect the natural dynamics of biological processes. Unlike traditional cell culture or fixed tissue imaging, IVM allows for the ultra-fast high-resolution imaging of cellular processes over time and space and were studied in its natural environment. Real-time visualization of biological processes in the context of an intact organism helps maintain physiological relevance and provide insights into the progression of disease, response to treatments or developmental processes. In this webinar we give an overview of advanced applications of the IVM system in preclinical research. IVIM technology is a provider of all-in-one intravital microscopy systems and solutions optimized for in vivo imaging of live animal models at sub-micron resolution. The system’s unique features and user-friendly software enables researchers to probe fast dynamic biological processes such as immune cell tracking, cell-cell interaction as well as vascularization and tumor metastasis with exceptional detail. This webinar will also give an overview of IVM being utilized in drug development, offering a view into the intricate interaction between drugs/nanoparticles and tissues in vivo and allows for the evaluation of therapeutic intervention in a variety of tissues and organs. This interdisciplinary collaboration continues to drive the advancements of novel therapeutic strategies. ]]>
Intravital microscopy (IVM) is a powerful tool utilized to study cellular behavior over time and space in vivo. Much of our understanding of cell biology has been accomplished using various in vitro and ex vivo methods; however, these studies do not necessarily reflect the natural dynamics of biological processes. Unlike traditional cell culture or fixed tissue imaging, IVM allows for the ultra-fast high-resolution imaging of cellular processes over time and space and were studied in its natural environment. Real-time visualization of biological processes in the context of an intact organism helps maintain physiological relevance and provide insights into the progression of disease, response to treatments or developmental processes. In this webinar we give an overview of advanced applications of the IVM system in preclinical research. IVIM technology is a provider of all-in-one intravital microscopy systems and solutions optimized for in vivo imaging of live animal models at sub-micron resolution. The system’s unique features and user-friendly software enables researchers to probe fast dynamic biological processes such as immune cell tracking, cell-cell interaction as well as vascularization and tumor metastasis with exceptional detail. This webinar will also give an overview of IVM being utilized in drug development, offering a view into the intricate interaction between drugs/nanoparticles and tissues in vivo and allows for the evaluation of therapeutic intervention in a variety of tissues and organs. This interdisciplinary collaboration continues to drive the advancements of novel therapeutic strategies. ]]> Wed, 29 May 2024 20:30:50 GMT /slideshow/may-29th-2024-advancements-in-intravital-microscopy-insights-for-preclinical-research-applications-pdf/269409622 scinticasam@slideshare.net(scinticasam) (May 29th, 2024) Advancements in Intravital Microscopy- Insights for Preclinical Research Applications.pdf scinticasam Intravital microscopy (IVM) is a powerful tool utilized to study cellular behavior over time and space in vivo. Much of our understanding of cell biology has been accomplished using various in vitro and ex vivo methods; however, these studies do not necessarily reflect the natural dynamics of biological processes. Unlike traditional cell culture or fixed tissue imaging, IVM allows for the ultra-fast high-resolution imaging of cellular processes over time and space and were studied in its natural environment. Real-time visualization of biological processes in the context of an intact organism helps maintain physiological relevance and provide insights into the progression of disease, response to treatments or developmental processes. In this webinar we give an overview of advanced applications of the IVM system in preclinical research. IVIM technology is a provider of all-in-one intravital microscopy systems and solutions optimized for in vivo imaging of live animal models at sub-micron resolution. The system’s unique features and user-friendly software enables researchers to probe fast dynamic biological processes such as immune cell tracking, cell-cell interaction as well as vascularization and tumor metastasis with exceptional detail. This webinar will also give an overview of IVM being utilized in drug development, offering a view into the intricate interaction between drugs/nanoparticles and tissues in vivo and allows for the evaluation of therapeutic intervention in a variety of tissues and organs. This interdisciplinary collaboration continues to drive the advancements of novel therapeutic strategies. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/may29th2024advancementsinintravitalmicroscopy-insightsforpreclinicalresearchapplications-240529203050-30a1f29a-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Intravital microscopy (IVM) is a powerful tool utilized to study cellular behavior over time and space in vivo. Much of our understanding of cell biology has been accomplished using various in vitro and ex vivo methods; however, these studies do not necessarily reflect the natural dynamics of biological processes. Unlike traditional cell culture or fixed tissue imaging, IVM allows for the ultra-fast high-resolution imaging of cellular processes over time and space and were studied in its natural environment. Real-time visualization of biological processes in the context of an intact organism helps maintain physiological relevance and provide insights into the progression of disease, response to treatments or developmental processes. In this webinar we give an overview of advanced applications of the IVM system in preclinical research. IVIM technology is a provider of all-in-one intravital microscopy systems and solutions optimized for in vivo imaging of live animal models at sub-micron resolution. The system’s unique features and user-friendly software enables researchers to probe fast dynamic biological processes such as immune cell tracking, cell-cell interaction as well as vascularization and tumor metastasis with exceptional detail. This webinar will also give an overview of IVM being utilized in drug development, offering a view into the intricate interaction between drugs/nanoparticles and tissues in vivo and allows for the evaluation of therapeutic intervention in a variety of tissues and organs. This interdisciplinary collaboration continues to drive the advancements of novel therapeutic strategies.
(May 29th, 2024) Advancements in Intravital Microscopy- Insights for Preclinical Research Applications.pdf from Scintica Instrumentation
]]> 117 0 https://cdn.slidesharecdn.com/ss_thumbnails/may29th2024advancementsinintravitalmicroscopy-insightsforpreclinicalresearchapplications-240529203050-30a1f29a-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 M-finite applications of the M-Series (MRI) Presentation​.pptx /slideshow/m-finite-applications-of-the-m-series-mri-presentation-pptx/268933716 umnwebinarpresentation-240521155918-81dd94d8
This presentation highlights the applications and capabilities of the M-Seriesâ„¢ compact MRI systems. Anatomical, functional, and molecular imaging can be performed on the M-Series and are often applied in cancer, cardiac, neuroscience, and multimodal imaging studies. It showcases example data from a variety of papers and training sessions in which the focus is on anatomy, neurobiology, and oncology. The presentation shows data from contrast agents which further enhances the capabilities of the M-Series, providing invaluable insights into tissue/tumor perfusion, myocardial infarction size, and molecular targets.]]>
This presentation highlights the applications and capabilities of the M-Series™ compact MRI systems. Anatomical, functional, and molecular imaging can be performed on the M-Series and are often applied in cancer, cardiac, neuroscience, and multimodal imaging studies. It showcases example data from a variety of papers and training sessions in which the focus is on anatomy, neurobiology, and oncology. The presentation shows data from contrast agents which further enhances the capabilities of the M-Series, providing invaluable insights into tissue/tumor perfusion, myocardial infarction size, and molecular targets.]]> Tue, 21 May 2024 15:59:18 GMT /slideshow/m-finite-applications-of-the-m-series-mri-presentation-pptx/268933716 scinticasam@slideshare.net(scinticasam) M-finite applications of the M-Series (MRI) Presentation​.pptx scinticasam This presentation highlights the applications and capabilities of the M-Series™ compact MRI systems. Anatomical, functional, and molecular imaging can be performed on the M-Series and are often applied in cancer, cardiac, neuroscience, and multimodal imaging studies. It showcases example data from a variety of papers and training sessions in which the focus is on anatomy, neurobiology, and oncology. The presentation shows data from contrast agents which further enhances the capabilities of the M-Series, providing invaluable insights into tissue/tumor perfusion, myocardial infarction size, and molecular targets. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/umnwebinarpresentation-240521155918-81dd94d8-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> This presentation highlights the applications and capabilities of the M-Series™ compact MRI systems. Anatomical, functional, and molecular imaging can be performed on the M-Series and are often applied in cancer, cardiac, neuroscience, and multimodal imaging studies. It showcases example data from a variety of papers and training sessions in which the focus is on anatomy, neurobiology, and oncology. The presentation shows data from contrast agents which further enhances the capabilities of the M-Series, providing invaluable insights into tissue/tumor perfusion, myocardial infarction size, and molecular targets.
M-finite applications of the M-Series (MRI) Presentation​.pptx from Scintica Instrumentation
]]> 63 0 https://cdn.slidesharecdn.com/ss_thumbnails/umnwebinarpresentation-240521155918-81dd94d8-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 (May 9, 2024) Enhanced Ultrafast Vector Flow Imaging (VFI) Using Multi-Angle Plane Waves /slideshow/may-9-2024-enhanced-ultrafast-vector-flow-imaging-vfi-using-multi-angle-plane-waves/267958083 vfiwebinarfinal1-240509184849-b68a1482
Ultrasound color Doppler imaging has been routinely used for the diagnosis of cardiovascular diseases, enabling real-time flow visualization through the Doppler effect. Yet, its inability to provide true flow velocity vectors due to its one-dimensional detection limits its efficacy. To overcome this limitation, various VFI schemes, including multi-angle beams, speckle tracking, and transverse oscillation, have been explored, with some already available commercially. However, many of these methods still rely on autocorrelation, which poses inherent issues such as underestimation, aliasing, and the need for large ensemble sizes. Conversely, speckle-tracking-based VFI enables lateral velocity estimation but suffers from significantly lower accuracy compared to axial velocity measurements.  To address these challenges, we have presented a speckle-tracking-based VFI approach utilizing multi-angle ultrafast plane wave imaging. Our approach involves estimating axial velocity components projected onto individual steered plane waves, which are then combined to derive the velocity vector. Additionally, we've introduced a VFI visualization technique with high spatial and temporal resolutions capable of tracking flow particle trajectories.  Simulation and flow phantom experiments demonstrate that the proposed VFI method outperforms both speckle-tracking-based VFI and autocorrelation VFI counterparts by at least a factor of three. Furthermore, in vivo measurements on carotid arteries using the Prodigy ultrasound scanner demonstrate the effectiveness of our approach compared to existing methods, providing a more robust imaging tool for hemodynamic studies.  Learning objectives:   - Understand fundamental limitations of color Doppler imaging.  - Understand principles behind advanced vector flow imaging techniques.  - Familiarize with the ultrasound speckle tracking technique and its implications in flow imaging.  - Explore experiments conducted using multi-angle plane wave ultrafast imaging, specifically utilizing the pulse-sequence mode on a 128-channel ultrasound research platform. ]]>
Ultrasound color Doppler imaging has been routinely used for the diagnosis of cardiovascular diseases, enabling real-time flow visualization through the Doppler effect. Yet, its inability to provide true flow velocity vectors due to its one-dimensional detection limits its efficacy. To overcome this limitation, various VFI schemes, including multi-angle beams, speckle tracking, and transverse oscillation, have been explored, with some already available commercially. However, many of these methods still rely on autocorrelation, which poses inherent issues such as underestimation, aliasing, and the need for large ensemble sizes. Conversely, speckle-tracking-based VFI enables lateral velocity estimation but suffers from significantly lower accuracy compared to axial velocity measurements.  To address these challenges, we have presented a speckle-tracking-based VFI approach utilizing multi-angle ultrafast plane wave imaging. Our approach involves estimating axial velocity components projected onto individual steered plane waves, which are then combined to derive the velocity vector. Additionally, we've introduced a VFI visualization technique with high spatial and temporal resolutions capable of tracking flow particle trajectories.  Simulation and flow phantom experiments demonstrate that the proposed VFI method outperforms both speckle-tracking-based VFI and autocorrelation VFI counterparts by at least a factor of three. Furthermore, in vivo measurements on carotid arteries using the Prodigy ultrasound scanner demonstrate the effectiveness of our approach compared to existing methods, providing a more robust imaging tool for hemodynamic studies.  Learning objectives:   - Understand fundamental limitations of color Doppler imaging.  - Understand principles behind advanced vector flow imaging techniques.  - Familiarize with the ultrasound speckle tracking technique and its implications in flow imaging.  - Explore experiments conducted using multi-angle plane wave ultrafast imaging, specifically utilizing the pulse-sequence mode on a 128-channel ultrasound research platform. ]]> Thu, 09 May 2024 18:48:49 GMT /slideshow/may-9-2024-enhanced-ultrafast-vector-flow-imaging-vfi-using-multi-angle-plane-waves/267958083 scinticasam@slideshare.net(scinticasam) (May 9, 2024) Enhanced Ultrafast Vector Flow Imaging (VFI) Using Multi-Angle Plane Waves scinticasam Ultrasound color Doppler imaging has been routinely used for the diagnosis of cardiovascular diseases, enabling real-time flow visualization through the Doppler effect. Yet, its inability to provide true flow velocity vectors due to its one-dimensional detection limits its efficacy. To overcome this limitation, various VFI schemes, including multi-angle beams, speckle tracking, and transverse oscillation, have been explored, with some already available commercially. However, many of these methods still rely on autocorrelation, which poses inherent issues such as underestimation, aliasing, and the need for large ensemble sizes. Conversely, speckle-tracking-based VFI enables lateral velocity estimation but suffers from significantly lower accuracy compared to axial velocity measurements.  To address these challenges, we have presented a speckle-tracking-based VFI approach utilizing multi-angle ultrafast plane wave imaging. Our approach involves estimating axial velocity components projected onto individual steered plane waves, which are then combined to derive the velocity vector. Additionally, we've introduced a VFI visualization technique with high spatial and temporal resolutions capable of tracking flow particle trajectories.  Simulation and flow phantom experiments demonstrate that the proposed VFI method outperforms both speckle-tracking-based VFI and autocorrelation VFI counterparts by at least a factor of three. Furthermore, in vivo measurements on carotid arteries using the Prodigy ultrasound scanner demonstrate the effectiveness of our approach compared to existing methods, providing a more robust imaging tool for hemodynamic studies.  Learning objectives:   - Understand fundamental limitations of color Doppler imaging.  - Understand principles behind advanced vector flow imaging techniques.  - Familiarize with the ultrasound speckle tracking technique and its implications in flow imaging.  - Explore experiments conducted using multi-angle plane wave ultrafast imaging, specifically utilizing the pulse-sequence mode on a 128-channel ultrasound research platform.  <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/vfiwebinarfinal1-240509184849-b68a1482-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Ultrasound color Doppler imaging has been routinely used for the diagnosis of cardiovascular diseases, enabling real-time flow visualization through the Doppler effect. Yet, its inability to provide true flow velocity vectors due to its one-dimensional detection limits its efficacy. To overcome this limitation, various VFI schemes, including multi-angle beams, speckle tracking, and transverse oscillation, have been explored, with some already available commercially. However, many of these methods still rely on autocorrelation, which poses inherent issues such as underestimation, aliasing, and the need for large ensemble sizes. Conversely, speckle-tracking-based VFI enables lateral velocity estimation but suffers from significantly lower accuracy compared to axial velocity measurements.  To address these challenges, we have presented a speckle-tracking-based VFI approach utilizing multi-angle ultrafast plane wave imaging. Our approach involves estimating axial velocity components projected onto individual steered plane waves, which are then combined to derive the velocity vector. Additionally, we&#39;ve introduced a VFI visualization technique with high spatial and temporal resolutions capable of tracking flow particle trajectories.  Simulation and flow phantom experiments demonstrate that the proposed VFI method outperforms both speckle-tracking-based VFI and autocorrelation VFI counterparts by at least a factor of three. Furthermore, in vivo measurements on carotid arteries using the Prodigy ultrasound scanner demonstrate the effectiveness of our approach compared to existing methods, providing a more robust imaging tool for hemodynamic studies.  Learning objectives:   - Understand fundamental limitations of color Doppler imaging.  - Understand principles behind advanced vector flow imaging techniques.  - Familiarize with the ultrasound speckle tracking technique and its implications in flow imaging.  - Explore experiments conducted using multi-angle plane wave ultrafast imaging, specifically utilizing the pulse-sequence mode on a 128-channel ultrasound research platform. 
(May 9, 2024) Enhanced Ultrafast Vector Flow Imaging (VFI) Using Multi-Angle Plane Waves from Scintica Instrumentation
]]> 232 0 https://cdn.slidesharecdn.com/ss_thumbnails/vfiwebinarfinal1-240509184849-b68a1482-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 Accelerating the Delivery of New Treatments for Children with Neuroblastoma 2024.pptx /slideshow/accelerating-the-delivery-of-new-treatments-for-children-with-neuroblastoma-2024pptx/267504423 acceleratingthedeliveryofnewtreatmentsforchildrenwithneuroblastoma2024-240424191010-30934ecc
Neuroblastoma is a tumour arising from anomalies in the development of the sympathic nervous system and still accounts for 13% of all cancer-related death in children due to resistant, relapsing and metastatic diseases. There is an urgent need for the development of new treatment against high-risk relapsed neuroblastoma. Overview: Here we will discuss the ICR Paediatric Mouse Hospital approach which integrates more advanced mouse modelling, such as the use of genetically-engineered mouse (GEM) models and patient-derived xenografts to accelerate the discovery and evaluation of novel therapeutic strategies and help shape the clinical trial pipeline priorities for children with high-risk relapsing/refractory neuroblastoma. We will also highlight the pivotal role of MRI within the Mouse Hospital which includes: Enhancing and accelerating preclinical trials Quantitatively inform on tumour phenotype and tumour response to treatment to: Develop in vivo models that emulate the clinical treatment resistant phenotype using chemotherapy-dose escalation protocol Characterize tumour spatial heterogeneity and evolution over treatment and guide the pathological and molecular characterization of the resistant phenotype Finally we will also discuss how the compact, cryogen-free and user-friendly Aspect Imaging M-Series has transformed our way of working within the mouse hospital by providing a shared and easily accessible resource for tumour screening (with minimal onboarding) .]]>
Neuroblastoma is a tumour arising from anomalies in the development of the sympathic nervous system and still accounts for 13% of all cancer-related death in children due to resistant, relapsing and metastatic diseases. There is an urgent need for the development of new treatment against high-risk relapsed neuroblastoma. Overview: Here we will discuss the ICR Paediatric Mouse Hospital approach which integrates more advanced mouse modelling, such as the use of genetically-engineered mouse (GEM) models and patient-derived xenografts to accelerate the discovery and evaluation of novel therapeutic strategies and help shape the clinical trial pipeline priorities for children with high-risk relapsing/refractory neuroblastoma. We will also highlight the pivotal role of MRI within the Mouse Hospital which includes: Enhancing and accelerating preclinical trials Quantitatively inform on tumour phenotype and tumour response to treatment to: Develop in vivo models that emulate the clinical treatment resistant phenotype using chemotherapy-dose escalation protocol Characterize tumour spatial heterogeneity and evolution over treatment and guide the pathological and molecular characterization of the resistant phenotype Finally we will also discuss how the compact, cryogen-free and user-friendly Aspect Imaging M-Series has transformed our way of working within the mouse hospital by providing a shared and easily accessible resource for tumour screening (with minimal onboarding) .]]> Wed, 24 Apr 2024 19:10:09 GMT /slideshow/accelerating-the-delivery-of-new-treatments-for-children-with-neuroblastoma-2024pptx/267504423 scinticasam@slideshare.net(scinticasam) Accelerating the Delivery of New Treatments for Children with Neuroblastoma 2024.pptx scinticasam Neuroblastoma is a tumour arising from anomalies in the development of the sympathic nervous system and still accounts for 13% of all cancer-related death in children due to resistant, relapsing and metastatic diseases. There is an urgent need for the development of new treatment against high-risk relapsed neuroblastoma. Overview: Here we will discuss the ICR Paediatric Mouse Hospital approach which integrates more advanced mouse modelling, such as the use of genetically-engineered mouse (GEM) models and patient-derived xenografts to accelerate the discovery and evaluation of novel therapeutic strategies and help shape the clinical trial pipeline priorities for children with high-risk relapsing/refractory neuroblastoma. We will also highlight the pivotal role of MRI within the Mouse Hospital which includes: Enhancing and accelerating preclinical trials Quantitatively inform on tumour phenotype and tumour response to treatment to: Develop in vivo models that emulate the clinical treatment resistant phenotype using chemotherapy-dose escalation protocol Characterize tumour spatial heterogeneity and evolution over treatment and guide the pathological and molecular characterization of the resistant phenotype Finally we will also discuss how the compact, cryogen-free and user-friendly Aspect Imaging M-Series has transformed our way of working within the mouse hospital by providing a shared and easily accessible resource for tumour screening (with minimal onboarding) . <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/acceleratingthedeliveryofnewtreatmentsforchildrenwithneuroblastoma2024-240424191010-30934ecc-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Neuroblastoma is a tumour arising from anomalies in the development of the sympathic nervous system and still accounts for 13% of all cancer-related death in children due to resistant, relapsing and metastatic diseases. There is an urgent need for the development of new treatment against high-risk relapsed neuroblastoma. Overview: Here we will discuss the ICR Paediatric Mouse Hospital approach which integrates more advanced mouse modelling, such as the use of genetically-engineered mouse (GEM) models and patient-derived xenografts to accelerate the discovery and evaluation of novel therapeutic strategies and help shape the clinical trial pipeline priorities for children with high-risk relapsing/refractory neuroblastoma. We will also highlight the pivotal role of MRI within the Mouse Hospital which includes: Enhancing and accelerating preclinical trials Quantitatively inform on tumour phenotype and tumour response to treatment to: Develop in vivo models that emulate the clinical treatment resistant phenotype using chemotherapy-dose escalation protocol Characterize tumour spatial heterogeneity and evolution over treatment and guide the pathological and molecular characterization of the resistant phenotype Finally we will also discuss how the compact, cryogen-free and user-friendly Aspect Imaging M-Series has transformed our way of working within the mouse hospital by providing a shared and easily accessible resource for tumour screening (with minimal onboarding) .
Accelerating the Delivery of New Treatments for Children with Neuroblastoma 2024.pptx from Scintica Instrumentation
]]> 69 0 https://cdn.slidesharecdn.com/ss_thumbnails/acceleratingthedeliveryofnewtreatmentsforchildrenwithneuroblastoma2024-240424191010-30934ecc-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 (March 14, 2024) Webinar: Validation of DEXA for Longitudinal Quantification of Tumor Burden in A Murine Model of Pancreatic Ductal Adenocarcinoma /slideshow/march-14-2024-webinar-validation-of-dexa-for-longitudinal-quantification-of-tumor-burden-in-a-murine-model-of-pancreatic-ductal-adenocarcinoma/266793455 sechristscinticawebinar3-14-24-240314205449-01feef32
Noninvasive imaging is central to preclinical, in vivo models of pancreatic ductal adenocarcinoma (PDAC). While bioluminescent imaging (BLI) is a gold standard, its signal is dependent on the metabolic activity of tumor cells. In contrast, dual energy X-ray absorptiometry (DEXA) is a direct measure of body composition. Thus, this project aimed to assess the potential of using DEXA for longitudinal quantification of tumor burden versus BLI in an orthotopic KCKO murine model of PDAC. In short, DEXA successfully identified a growing tumor burden and accurately predicts ex vivo tumor mass in a time sensitive manner. Learning objectives: Learn to take advantage of DEXA for things other than bone density and bone health (i.e., lean, and fat mass) Understand that DEXA can reproducibly and accurately be used to monitor tumor burden and growth in orthotopic murine models of pancreatic cancer Understand the importance of repurposing techniques and equipment for new analysis Understand that non-invasive in vivo imaging is crucially important in severely compromised models like those for PDAC and other cancers See the value of utilizing multiple techniques throughout an experiment to enhance data collection]]>
Noninvasive imaging is central to preclinical, in vivo models of pancreatic ductal adenocarcinoma (PDAC). While bioluminescent imaging (BLI) is a gold standard, its signal is dependent on the metabolic activity of tumor cells. In contrast, dual energy X-ray absorptiometry (DEXA) is a direct measure of body composition. Thus, this project aimed to assess the potential of using DEXA for longitudinal quantification of tumor burden versus BLI in an orthotopic KCKO murine model of PDAC. In short, DEXA successfully identified a growing tumor burden and accurately predicts ex vivo tumor mass in a time sensitive manner. Learning objectives: Learn to take advantage of DEXA for things other than bone density and bone health (i.e., lean, and fat mass) Understand that DEXA can reproducibly and accurately be used to monitor tumor burden and growth in orthotopic murine models of pancreatic cancer Understand the importance of repurposing techniques and equipment for new analysis Understand that non-invasive in vivo imaging is crucially important in severely compromised models like those for PDAC and other cancers See the value of utilizing multiple techniques throughout an experiment to enhance data collection]]> Thu, 14 Mar 2024 20:54:49 GMT /slideshow/march-14-2024-webinar-validation-of-dexa-for-longitudinal-quantification-of-tumor-burden-in-a-murine-model-of-pancreatic-ductal-adenocarcinoma/266793455 scinticasam@slideshare.net(scinticasam) (March 14, 2024) Webinar: Validation of DEXA for Longitudinal Quantification of Tumor Burden in A Murine Model of Pancreatic Ductal Adenocarcinoma scinticasam Noninvasive imaging is central to preclinical, in vivo models of pancreatic ductal adenocarcinoma (PDAC). While bioluminescent imaging (BLI) is a gold standard, its signal is dependent on the metabolic activity of tumor cells. In contrast, dual energy X-ray absorptiometry (DEXA) is a direct measure of body composition. Thus, this project aimed to assess the potential of using DEXA for longitudinal quantification of tumor burden versus BLI in an orthotopic KCKO murine model of PDAC. In short, DEXA successfully identified a growing tumor burden and accurately predicts ex vivo tumor mass in a time sensitive manner. Learning objectives: Learn to take advantage of DEXA for things other than bone density and bone health (i.e., lean, and fat mass) Understand that DEXA can reproducibly and accurately be used to monitor tumor burden and growth in orthotopic murine models of pancreatic cancer Understand the importance of repurposing techniques and equipment for new analysis Understand that non-invasive in vivo imaging is crucially important in severely compromised models like those for PDAC and other cancers See the value of utilizing multiple techniques throughout an experiment to enhance data collection <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/sechristscinticawebinar3-14-24-240314205449-01feef32-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Noninvasive imaging is central to preclinical, in vivo models of pancreatic ductal adenocarcinoma (PDAC). While bioluminescent imaging (BLI) is a gold standard, its signal is dependent on the metabolic activity of tumor cells. In contrast, dual energy X-ray absorptiometry (DEXA) is a direct measure of body composition. Thus, this project aimed to assess the potential of using DEXA for longitudinal quantification of tumor burden versus BLI in an orthotopic KCKO murine model of PDAC. In short, DEXA successfully identified a growing tumor burden and accurately predicts ex vivo tumor mass in a time sensitive manner. Learning objectives: Learn to take advantage of DEXA for things other than bone density and bone health (i.e., lean, and fat mass) Understand that DEXA can reproducibly and accurately be used to monitor tumor burden and growth in orthotopic murine models of pancreatic cancer Understand the importance of repurposing techniques and equipment for new analysis Understand that non-invasive in vivo imaging is crucially important in severely compromised models like those for PDAC and other cancers See the value of utilizing multiple techniques throughout an experiment to enhance data collection
(March 14, 2024) Webinar: Validation of DEXA for Longitudinal Quantification of Tumor Burden in A Murine Model of Pancreatic Ductal Adenocarcinoma from Scintica Instrumentation
]]> 54 0 https://cdn.slidesharecdn.com/ss_thumbnails/sechristscinticawebinar3-14-24-240314205449-01feef32-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 (March 13, 2024) Overview of Preclinical Small Animal and Multimodal Imaging /slideshow/march-13-2024-overview-of-preclinical-small-animal-and-multimodal-imaging/266770581 multimodalimagingwebinar-240313153657-9a79bdc0
In this webinar, we reviewed some of the most commonly used preclinical imaging modalities, including magnetic resonance imaging (MRI), positron emission tomography (PET), computer tomography (CT), ultrasound, photoacoustic, bioluminescence, fluorescence, dual-energy x-ray absorptiometry (DEXA/DXA), and intravital microscopy. For each modality, we spent time reviewing the basics of how each worked, the strengths and considerations of each, and some key application areas and example images. Finally, we discussed the benefits of multimodal imaging and reviewed a few papers utilizing a variety of imaging modalities to help support their research outcomes. We ended with a very brief introduction to Scintica Instrumentation and our philosophy behind the various products we represented. However, the main focus of the webinar was on education, and not our diverse product portfolio.]]>
In this webinar, we reviewed some of the most commonly used preclinical imaging modalities, including magnetic resonance imaging (MRI), positron emission tomography (PET), computer tomography (CT), ultrasound, photoacoustic, bioluminescence, fluorescence, dual-energy x-ray absorptiometry (DEXA/DXA), and intravital microscopy. For each modality, we spent time reviewing the basics of how each worked, the strengths and considerations of each, and some key application areas and example images. Finally, we discussed the benefits of multimodal imaging and reviewed a few papers utilizing a variety of imaging modalities to help support their research outcomes. We ended with a very brief introduction to Scintica Instrumentation and our philosophy behind the various products we represented. However, the main focus of the webinar was on education, and not our diverse product portfolio.]]> Wed, 13 Mar 2024 15:36:57 GMT /slideshow/march-13-2024-overview-of-preclinical-small-animal-and-multimodal-imaging/266770581 scinticasam@slideshare.net(scinticasam) (March 13, 2024) Overview of Preclinical Small Animal and Multimodal Imaging scinticasam In this webinar, we reviewed some of the most commonly used preclinical imaging modalities, including magnetic resonance imaging (MRI), positron emission tomography (PET), computer tomography (CT), ultrasound, photoacoustic, bioluminescence, fluorescence, dual-energy x-ray absorptiometry (DEXA/DXA), and intravital microscopy. For each modality, we spent time reviewing the basics of how each worked, the strengths and considerations of each, and some key application areas and example images. Finally, we discussed the benefits of multimodal imaging and reviewed a few papers utilizing a variety of imaging modalities to help support their research outcomes. We ended with a very brief introduction to Scintica Instrumentation and our philosophy behind the various products we represented. However, the main focus of the webinar was on education, and not our diverse product portfolio. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/multimodalimagingwebinar-240313153657-9a79bdc0-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> In this webinar, we reviewed some of the most commonly used preclinical imaging modalities, including magnetic resonance imaging (MRI), positron emission tomography (PET), computer tomography (CT), ultrasound, photoacoustic, bioluminescence, fluorescence, dual-energy x-ray absorptiometry (DEXA/DXA), and intravital microscopy. For each modality, we spent time reviewing the basics of how each worked, the strengths and considerations of each, and some key application areas and example images. Finally, we discussed the benefits of multimodal imaging and reviewed a few papers utilizing a variety of imaging modalities to help support their research outcomes. We ended with a very brief introduction to Scintica Instrumentation and our philosophy behind the various products we represented. However, the main focus of the webinar was on education, and not our diverse product portfolio.
(March 13, 2024) Overview of Preclinical Small Animal and Multimodal Imaging from Scintica Instrumentation
]]> 215 0 https://cdn.slidesharecdn.com/ss_thumbnails/multimodalimagingwebinar-240313153657-9a79bdc0-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 (September 20, 2023) Webinar: An Introduction to Photoacoustic Imaging /slideshow/september-20-2023-webinar-an-introduction-to-photoacoustic-imaging/261205214 tritomwebinar-230920174004-668a8155
Dr. Lawrence Yip explained how Photoacoustic (PA) imaging works, where it fits in with other modalities and, how your research could benefit from this emerging technology. Excellent spatial resolution, depth penetration, and superior contrast are just some of the advantages often associated with PA imaging. In this webinar, we dove into the advantages, where they can be beneficial, and how the TriTom’s patented technology overcomes some of the challenges experienced by early adopters of this imaging modality. The TriTom is a turnkey, compact, tabletop imaging system that combines the sensitivity of fluorescence molecular tomography with the depth penetration and spatial resolution of PA tomography. Many applications including cancer, neuroimaging, developmental biology, and cardiovascular research could benefit from adding these imaging modalities, and we will draw from literature and concrete examples to demonstrate this advantage. ]]>
Dr. Lawrence Yip explained how Photoacoustic (PA) imaging works, where it fits in with other modalities and, how your research could benefit from this emerging technology. Excellent spatial resolution, depth penetration, and superior contrast are just some of the advantages often associated with PA imaging. In this webinar, we dove into the advantages, where they can be beneficial, and how the TriTom’s patented technology overcomes some of the challenges experienced by early adopters of this imaging modality. The TriTom is a turnkey, compact, tabletop imaging system that combines the sensitivity of fluorescence molecular tomography with the depth penetration and spatial resolution of PA tomography. Many applications including cancer, neuroimaging, developmental biology, and cardiovascular research could benefit from adding these imaging modalities, and we will draw from literature and concrete examples to demonstrate this advantage. ]]> Wed, 20 Sep 2023 17:40:04 GMT /slideshow/september-20-2023-webinar-an-introduction-to-photoacoustic-imaging/261205214 scinticasam@slideshare.net(scinticasam) (September 20, 2023) Webinar: An Introduction to Photoacoustic Imaging scinticasam Dr. Lawrence Yip explained how Photoacoustic (PA) imaging works, where it fits in with other modalities and, how your research could benefit from this emerging technology. Excellent spatial resolution, depth penetration, and superior contrast are just some of the advantages often associated with PA imaging. In this webinar, we dove into the advantages, where they can be beneficial, and how the TriTom’s patented technology overcomes some of the challenges experienced by early adopters of this imaging modality. The TriTom is a turnkey, compact, tabletop imaging system that combines the sensitivity of fluorescence molecular tomography with the depth penetration and spatial resolution of PA tomography. Many applications including cancer, neuroimaging, developmental biology, and cardiovascular research could benefit from adding these imaging modalities, and we will draw from literature and concrete examples to demonstrate this advantage. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/tritomwebinar-230920174004-668a8155-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Dr. Lawrence Yip explained how Photoacoustic (PA) imaging works, where it fits in with other modalities and, how your research could benefit from this emerging technology. Excellent spatial resolution, depth penetration, and superior contrast are just some of the advantages often associated with PA imaging. In this webinar, we dove into the advantages, where they can be beneficial, and how the TriTom’s patented technology overcomes some of the challenges experienced by early adopters of this imaging modality. The TriTom is a turnkey, compact, tabletop imaging system that combines the sensitivity of fluorescence molecular tomography with the depth penetration and spatial resolution of PA tomography. Many applications including cancer, neuroimaging, developmental biology, and cardiovascular research could benefit from adding these imaging modalities, and we will draw from literature and concrete examples to demonstrate this advantage.
(September 20, 2023) Webinar: An Introduction to Photoacoustic Imaging from Scintica Instrumentation
]]> 108 0 https://cdn.slidesharecdn.com/ss_thumbnails/tritomwebinar-230920174004-668a8155-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 (September 13, 2023) Webinar: Seeing Double: Preclinical Multiplexed PET for Dual Isotope Imaging /slideshow/september-13-2023-webinar-seeing-double-preclinical-multiplexed-pet-for-dual-isotope-imaging/260955293 scinticaseminarmpet13-sep-2023-230914144149-01800750
Overview: In this webinar, Dr. Edwin C. Pratt discussed the realm of positron emission tomography (PET) imaging and explained the innovative concept of multiplexed PET. This new scientific advancement makes it possible to perform simultaneous imaging with two different isotopes providing more in depth information with a single scan. Key Takeaways: Multiplexed PET is a new reconstruction method to identify and separate positron from positron-prompt gamma emissions without new hardware from list mode PET scanners or energy discrimination of events. Multiplexed PET is a quantitative method that is agnostic to the type of radiotracer used (IE no compartment modeling). Only a simple uniformity and sensitivity phantom is required. Acquisition has been shown in a variety of preclinical and clinical PET scanners, though not all scanners can natively acquire data for multiplexing. Multiplexed PET enables faster throughput for screening radiotracers, or conversely two tracer information of a tissue of interest, like imaging the tumor microenvironment for two immune populations.]]>
Overview: In this webinar, Dr. Edwin C. Pratt discussed the realm of positron emission tomography (PET) imaging and explained the innovative concept of multiplexed PET. This new scientific advancement makes it possible to perform simultaneous imaging with two different isotopes providing more in depth information with a single scan. Key Takeaways: Multiplexed PET is a new reconstruction method to identify and separate positron from positron-prompt gamma emissions without new hardware from list mode PET scanners or energy discrimination of events. Multiplexed PET is a quantitative method that is agnostic to the type of radiotracer used (IE no compartment modeling). Only a simple uniformity and sensitivity phantom is required. Acquisition has been shown in a variety of preclinical and clinical PET scanners, though not all scanners can natively acquire data for multiplexing. Multiplexed PET enables faster throughput for screening radiotracers, or conversely two tracer information of a tissue of interest, like imaging the tumor microenvironment for two immune populations.]]> Thu, 14 Sep 2023 14:41:49 GMT /slideshow/september-13-2023-webinar-seeing-double-preclinical-multiplexed-pet-for-dual-isotope-imaging/260955293 scinticasam@slideshare.net(scinticasam) (September 13, 2023) Webinar: Seeing Double: Preclinical Multiplexed PET for Dual Isotope Imaging scinticasam Overview: In this webinar, Dr. Edwin C. Pratt discussed the realm of positron emission tomography (PET) imaging and explained the innovative concept of multiplexed PET. This new scientific advancement makes it possible to perform simultaneous imaging with two different isotopes providing more in depth information with a single scan. Key Takeaways: Multiplexed PET is a new reconstruction method to identify and separate positron from positron-prompt gamma emissions without new hardware from list mode PET scanners or energy discrimination of events. Multiplexed PET is a quantitative method that is agnostic to the type of radiotracer used (IE no compartment modeling). Only a simple uniformity and sensitivity phantom is required. Acquisition has been shown in a variety of preclinical and clinical PET scanners, though not all scanners can natively acquire data for multiplexing. Multiplexed PET enables faster throughput for screening radiotracers, or conversely two tracer information of a tissue of interest, like imaging the tumor microenvironment for two immune populations. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/scinticaseminarmpet13-sep-2023-230914144149-01800750-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Overview: In this webinar, Dr. Edwin C. Pratt discussed the realm of positron emission tomography (PET) imaging and explained the innovative concept of multiplexed PET. This new scientific advancement makes it possible to perform simultaneous imaging with two different isotopes providing more in depth information with a single scan. Key Takeaways: Multiplexed PET is a new reconstruction method to identify and separate positron from positron-prompt gamma emissions without new hardware from list mode PET scanners or energy discrimination of events. Multiplexed PET is a quantitative method that is agnostic to the type of radiotracer used (IE no compartment modeling). Only a simple uniformity and sensitivity phantom is required. Acquisition has been shown in a variety of preclinical and clinical PET scanners, though not all scanners can natively acquire data for multiplexing. Multiplexed PET enables faster throughput for screening radiotracers, or conversely two tracer information of a tissue of interest, like imaging the tumor microenvironment for two immune populations.
(September 13, 2023) Webinar: Seeing Double: Preclinical Multiplexed PET for Dual Isotope Imaging from Scintica Instrumentation
]]> 128 0 https://cdn.slidesharecdn.com/ss_thumbnails/scinticaseminarmpet13-sep-2023-230914144149-01800750-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 0 https://cdn.slidesharecdn.com/profile-photo-scinticasam-48x48.jpg?cb=1749837926 Scintica Instrumentation offers investigative tools for basic science and translational research. Key application are cardiovascular, cancer, stem cells, hypoxia and neuroscience. - blood flow/pressure/ECG - tissue oxygenation - implantable and ex vivo solutions for whole animal and - - isolated organ studies - ventilation and anesthesia - surgical monitoring and temperature control in small animals - hypoxia incubators - colony counters Our imaging portfolio includes: - low field compact MRI - portable tablet 3D ultrasound system - miniature laser confocal endomicroscope www.scintica.com/ https://cdn.slidesharecdn.com/ss_thumbnails/insightdxa-livedemo-06122025-250613180548-ea506677-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/insight-dexa-live-lab-demonstration/280523305 iNSiGHT DEXA ----- Liv... https://cdn.slidesharecdn.com/ss_thumbnails/slides-anefficientandreliablemethodtodeterminespo2inrodents-250529190059-482650b8-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/an-efficient-and-reliable-method-to-determine-spo2-in-rodents-pdf/279882978 An Efficient and Relia... https://cdn.slidesharecdn.com/ss_thumbnails/20250306viscoverscinticawebinar1-250312135555-6be7754a-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/witness-the-power-of-contrast-agents-multimodal-imaging-mri-ultrasound-ct-optical/276610442 Witness the Power of C...